Abstract: Pharmacological profile of phytochemicals has attracted much attention to their use in disease therapy. Since cancer is a major problem for public health with high mortality and morbidity worldwide, experiments have focused on revealing the anti-tumor activity of natural products. Flavonoids comprise a large family of natural products with different categories. Chrysin is a hydroxylated flavonoid belonging to the flavone category. Chrysin has demonstrated great potential in treating different disorders, due to possessing biological and therapeutic activities, such as antioxidant, anti-inflammatory, hepatoprotective, neuroprotective, etc. Over recent years, the anti-tumor activity of chrysin has been investigated, and in the present review, we provide a mechanistic discussion of the inhibitory effect of chrysin on proliferation and invasion of different cancer cells. Molecular pathways, such as Notch1, microRNAs, signal transducer and activator of transcription 3 (STAT3), nuclear factor-kappaB (NF-κB), PI3K/Akt, MAPK, etc., as targets of chrysin are discussed. The efficiency of chrysin in promoting anti-tumor activity of chemotherapeutic agents and suppressing drug resistance is described. Moreover, poor bioavailability, as one of the drawbacks of chrysin, is improved using various nanocarriers, such as micelles, polymeric nanoparticles, etc. This updated review will provide a direction for further studies in evaluating the anti-tumor activity of chrysin.

Keywords: chrysin; cancer therapy; nanoparticle; flavonoid; chemotherapy

1. Introduction

Average living standards and access to sufficient healthcare have led to an increase in life expectancy in most regions of the world [1,2]. Although communicable disease-related deaths have been reduced as a result of medical improvements, we have witnessed a 40% increase in cancer-related
deaths in recent years. It seems that the number of patients with cancer will increase in the future, and there will be up to 13 million cancer-related deaths by 2030. There are different problems in providing effective cancer therapy, such as the insufficiency of currently applied treatments, lack of early diagnosis, and poor understanding of signaling networks involved in cancer malignancy. In spite of significant attempts in knowing factors contributing to cancer progression, there is not still an effective treatment for cancer [3–5]. This is due to the fact that each cancer type has its own features; for instance, cancer cells are different in terms of proliferation, metastasis, and dependence on molecular pathways. Furthermore, cancer cells can obtain resistance to currently applied chemotherapeutic agents [6,7]. Therefore, a novel agent capable of suppressing cancer growth and metastasis and preventing drug resistance is important. In the present review, we aim to reveal the anti-tumor activity of chrysin, as a naturally occurring compound against different cancers. We discuss the various molecular pathways that are affected by chrysin in cancer to direct further studies for investigating more signaling networks. In addition, we describe the role of chrysin in overcoming drug resistance in cancer therapy, which is a major problem in the clinic. Finally, we provide strategies in promoting the anti-tumor activity of chrysin using nanoparticles to enhance bioavailability and therapeutic effects of chrysin.

2. Role of Natural Products in Cancer Therapy

Nature is a rich source of compounds with different pharmacological activities [8–12]. The special view towards nature is due to the presence of anti-tumor agents with low toxicity, and capable of suppressing a wide variety of cancers [13–18]. Furthermore, natural products are more affordable compared to synthetic drugs. It seems that newly introduced anti-tumor drugs have high similarity to natural anti-tumor compounds. Therefore, identifying novel phytochemicals, making changes in their structure to promote their therapeutic effect, and introducing into the market can be considered as a new way in effective cancer therapy. Newly published experiments have clearly demonstrated the potential of phytochemicals in cancer therapy. The proliferation of cancer cells is suppressed upon the administration of natural anti-tumor compounds [19,20]. Apoptosis and cell cycle arrest can be induced via p53 up-regulation [21]. Based on the fact that poor bioavailability is one of the drawbacks of natural products, using nanoscale delivery systems can exponentially promote their anti-tumor activity against cancer cells for both in vitro and in vivo experiments [22–24]. In cancer cells, checkpoint gene expression enhances that provides uncontrolled growth. It has been reported that the administration of natural products is correlated with a decrease in checkpoint expression, and subsequent decrease in proliferation of cancer cells [25]. DNA damage, as well as the activation of both intrinsic and extrinsic pathways of apoptosis, occur during natural product administration in cancer therapy [26]. It is worth mentioning that naturally occurring compounds can promote the efficiency of chemotherapeutic agents in cancer therapy [27–29]. For instance, quercetin sensitizes prostate cancer cells to paclitaxel chemotherapy by enhancing reactive oxygen species (ROS) production, stimulation of endoplasmic reticulum (ER) stress, and activation of apoptosis [30]. Molecular pathways, such as MAPK and JNK, are regulated by natural products in apoptosis induction [31]. In addition to proliferation, migration, and invasion of cancer cells can be negatively targeted by natural products [32–34]. Increasing evidence confirms the role of epithelial-to-mesenchymal transition (EMT) in cancer metastasis [35–37]. Natural products are capable of suppressing the migration of cancer cells by EMT inhibition via down-regulation of upstream molecular pathways, such as Snail and STAT3 [38–40].

Taking everything into account, studies agree with the fact that natural products are versatile compounds in cancer therapy, and due to their capacity in targeting various molecular pathways in cancer therapy [41–45], they can be considered as potential agents in the field of cancer therapy. In the next sections, we focus on chrysin as an efficient anti-tumor agent in different cancers.

3. Chrysin: An Overview of Chemistry, Sources, and Pharmacokinetics

Flavonoids are the largest group of plant secondary metabolites with favorable health-promoting effects [46–49]. The interest in flavonoids has been increased, since these valuable compounds act
through various physiological mechanisms and affect a wide variety of signaling networks. Dietary intake of flavonoids is estimated to be 50 and 800 mg per day [50,51]. Chrysin is a hydroxylated flavonoid belonging to flavone class, and is extensively found in sources, such as honey, propolis, and plant species [52,53]. Noteworthy, chrysin occurs in natural sources with different concentrations. For instance, the concentration of chrysin in honeydew honey is 0.10 mg/kg, while it has a higher concentration (5.3 mg/kg) in forest honeys [54]. The content of chrysin in propolis is estimated to be 25 g/L [55]. Chrysin concentration in mushrooms is at the range of 0.17–0.34 mg/kg [56]. The IUPAC name of chrysin is 5,7-dihydroxy-2-phenyl-4H-chromen-4-one and 5,7-dihydroxyflavone. Figure 1 demonstrates the chemical structure of chrysin. The chrysin structure has similarities and differences with the flavonoid family. Structurally, chrysin has two benzene rings (A and B) with one oxygen consisting of a heterocyclic ring. Chrysin lacks a 3-carbon hydroxyl group, but it has 2–3 double-bound carbon with a carbonyl group attached to 4th carbon. The chemical structure of chrysin demonstrates that it has –OH group at 5th and 7th carbon atoms. There is a difference in the structure of chrysin and other flavonoids, so that chrysin does not possess any oxygenation in ring B (Figure 1). It has been reported that changes in ring A of chrysin account for the generation of different derivatives of chrysin, such as wogonin, baicalein, and oroxylin [57].

Accumulating data demonstrates that poor absorption, rapid metabolism, and systemic elimination are responsible for poor bioavailability of chrysin in humans that, subsequently, restrict its therapeutic effects [58]. It is worth mentioning that oxidation in intestinal and hepatic cells is not responsible for the metabolism of chrysin in the body. In contrast, conjugation pathways, such as glucuronidation and sulfation catalyze chrysin. Enzymes, such as P-PST, M-PST, and UGT1A6, contribute to the metabolism of chrysin, and their high affinity for chrysin can justify the poor bioavailability of this natural compound. Clinical studies have shown that the plasma concentration of chrysin following oral administration is very low [59]. Notably, serum concentrations of chrysin have not been reported yet, but it can be predicted based on other flavonoids. Since flavonoid aglycones demonstrate serum concentration as low as 1 μmol/L [60], the serum concentration of chrysin would be at the range of nanomolar. The studies related to the absorption of chrysin demonstrate that its sulfation and glucuronidation limit the absorption of this valuable compound in the intestine. MRP2 transporters are involved in the efflux of chrysin metabolites from the intestine, and in the lumen, sulfatases and glucuronidases hydrolyze metabolites into chrysin. This leads to the emergence of chrysin in stool,

![Chemical structure of chrysin](image-url)
but high contents of chrysin in stool demonstrates that it has low absorption [61]. Some strategies have been applied in promoting bioavailability and absorption of chrysin, such as using nanoscale delivery systems [62].

4. Chrysin and Its Pharmacological Activities

In previous sections, we provided explanations about the role of natural products in cancer therapy, and then, we introduced the chemistry and pharmacokinetics of chrysin. In this section, we aim to describe the pharmacological activities of chrysin, based on the newly published article—which is summarized in Table 1.

Increasing evidence demonstrates that chrysin possesses health-promoting effects, including antioxidant [63,64], anti-inflammatory [65], anti-diabetes [66], neuroprotective [67], hepatoprotective [68], cardioprotective [69], lipid-lowering effect [70], etc. These therapeutic effects have made chrysin as a suitable option in disease therapy. Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic disorders, and to date, natural products have shown great potential in the alleviation of NAFLD. Similarly, a recently recorded article has revealed that chrysin administration (25, 50, and 100 mg/kg) alleviates NAFLD in rats via reducing serum fasting glucose that subsequently improves insulin resistance and dyslipidemia. Noteworthy, chrysin can significantly diminish liver weight by reducing hepatic free fatty acids, triglyceride, and cholesterol content. Anti-inflammatory and antioxidant activities of chrysin are also involved in the amelioration of NAFLD via decreasing lobular inflammation, steatosis, and carbonyl content [71]. Many reports demonstrate that chrysin can be beneficial in reducing acetaminophen-mediated hepatotoxicity in rats. In this regard, chrysin reduces levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2). The ameliorative effect of chrysin on acetaminophen-mediated hepatotoxicity seems to be dose-dependent with more therapeutic effects at higher concentrations [72]. In addition to hepatoprotective activity, chrysin has shown potential neuroprotective effects. One of the complications causing neuronal cell death is ischemic-reperfusion (I/R) injury. Inflammation and oxidative stress are two main mechanisms involved in I/R injury [73–75]. Chrysin administration (10 and 20 mg/kg) reduces pro-inflammatory factors (TNF-α, IL-1β, and IL-6) and oxidative stress to alleviate cerebral I/R injury. Investigation of molecular pathways reveals that the induction of the PI3K/Akt signaling pathway by chrysin contributes to a reduction in oxidative stress and inflammation during cerebral I/R injury [76]. The inhibitory effect of chrysin on inflammation and oxidative stress is also important in Parkinson’s disease (PD) treatment [77]. Chrysin (25, 50, and 100 mg/kg) improves cognitive capacity, inflammation, and apoptosis to ameliorate traumatic brain injury (TBI) [78]. Overall, the literature confirms the health-promoting and therapeutic effects of chrysin that are important in disease therapy, and the effect of this valuable compound on molecular pathways (Figure 2) [79–82]. In the next sections, we specifically discuss the role of chrysin in cancer therapy [83,84].
Figure 2. A schematic representation of the health-promoting effects of chrysin in pre-clinical experiments.
Table 1. Various pharmacological activities of chrysin in treating diseases.

| Therapeutic Effect/Disease | In Vitro/In Vivo | Cell Line/Animal Model | Dose (In Vivo)/Concentration (In Vitro) | Duration of Experiment | Administration Route | Outcomes | Refs |
|----------------------------|------------------|------------------------|----------------------------------------|------------------------|---------------------|----------|------|
| Anti-hypertension          | In vivo          | Rat                    | 100 mg/kg                               | 18 weeks               | Oral administration | Decreasing systolic and diastolic pressures Reducing insulin, angiotensin II and triacylglycerols levels | [85] |
| Neuroprotective            | In vivo          | Rat                    | 10 and 30 mg/kg                         | 8 weeks                | Oral gavage         | Improving memory impairment Enhancing neuronal cell survival Reducing hippocampal neurogenesis depletion | [86] |
| Neuroprotective            | In vivo          | Rat                    | 10, 30, and 100 mg/kg                   | 3 weeks                | Oral administration | Enhancing GPx activity and number of surviving cells in hippocampus Reducing MDA, NO and PGE2 levels Improving passive avoidance memory | [87] |
| Cardioprotective           | In vitro         | Cardiomyocyte          | 10, 50, and 100 µM                      | 3 h                    | -                   | Decreasing aluminium-phosphide-mediated oxidative stress Reducing mitochondrial damage Improving mitochondrial function | [88] |
| Renoprotective Hepatoprotective | In vivo        | Rat                    | 100 mg/kg                               | -                      | -                   | Reinforcing antioxidant defense system via up-regulating GSH and SOD activities Reducing lipid peroxidation Decreasing inflammation via TNF-α down-regulation | [89] |
| Renoprotective Hepatoprotective | In vivo        | Rat                    | 25 and 50 mg/kg                         | 7 days                 | Oral administration | Reducing AST, ALT, ALP, urea, creatinine, MDA and hepatorenal deterioration Enhancing SOD, CAT, and GPx activities Apoptosis inhibition via Bcl-2 up-regulation and Bax down-regulation Reducing inflammation via NF-κB down-regulation | [90] |
| Anti-diabetic              | In vitro         | Chorioretinal endothelial cells | 1, 3, 10, 30, and 50 µM | 24 h                  | -                   | Reducing Akt, ERK, MMP-2, and VEGF expressions | [91] |
| Anti-diabetic              | In vivo          | Rat model of type 1 diabetes | 50 and 100 mg/kg | 28 days               | Oral gavage         | Reducing oxidative stress index Enhancing glutathione levels | [92] |
| Gastric healing            | In vivo          | Mouse model of gastric ulcer via ethanol | 10, 50, and 100 mg/kg | 7 and 14 days        | Oral administration | Apoptosis inhibition via caspase-3 down-regulation Reducing macroscopic lesions Enhancing catalase activity Improving inflammation via COX-2 down-regulation | [93] |
5. Chrysin and Cancer

5.1. Breast Cancer

Breast cancer is the most common and malignant cancer in women [94–96]. Recurrence and chemoresistance have restricted the efficacy of currently applied treatment in breast cancer therapy [97–100]. Natural products have demonstrated an excellent inhibitory effect on both proliferation and metastasis of breast cancer [101–104]. A combination of chrysin and silibinin is beneficial in suppressing breast cancer malignancy via decreasing cancer proliferation. Furthermore, chrysin and silibinin induced cell cycle arrest via down-regulation of cyclin D1 and hTERT [105]. The epidermal growth factor receptor (EGFR) is considered as a potential target in cancer therapy [106]. Standard chemotherapy reduces the replication of cancer cells, but EGFR inhibitors are capable of cancer proliferation and survival [107]. Therefore, using EGFR inhibitors, such as antibody-based immunoconjugates, monoclonal antibodies, antisense oligonucleotides, and small molecules is preferred to chemotherapy [108]. A new derivative of chrysin known as CHM-04 has been synthesized with affinity to EGFR. It seems that CHM-04 is a potent inhibitor of EGFR with more efficiency compared to chemotherapeutic agents in suppressing cancer malignancy. In triple-negative breast cancer cells treated with chrysin, sphere formation ability, proliferation, and migration are substantially suppressed that can be attributed to the inhibitory effect of CHM-04 on EGFR [109].

Low oxygen level is known as hypoxia, and is a common feature of solid tumors. Increasing evidence demonstrates that hypoxia is responsible for the growth and progression of cancer cells, and it is one of the best targets in cancer therapy [110–112]. Noteworthy, clinical studies revealed the relationship between hypoxia and cancer progression and metastasis [113,114]. In hypoxia, vascular endothelial growth factor (VEGF) is induced that promotes proliferation and invasion of cancer cells. Furthermore, hypoxia adaptation is mediated by hypoxia-inducible factor-1 (HIF-1) that is an efficient target in cancer therapy. In addition to HIF-1, other molecular pathways, such as signal transducer and activator of transcription 3 (STAT3), play a key role in hypoxia-mediated VEGF gene expression [115–118]. Administration of chrysin is associated with the disruption of hypoxia-induced VEGF gene expression. Moreover, chrysin is capable of reducing STAT3 phosphorylation in hypoxic conditions without affecting the HIF-1α protein level. In vitro and in vivo experiments agree with the fact that chrysin is a potent agent in suppressing metastasis and proliferation of breast cancer cells during hypoxic conditions, since chrysin abrogated lung metastasis of breast cancer cells [119].

Increasing evidence demonstrates that combination therapy is of interest in promoting the anti-tumor activity of agents. Although chrysin has demonstrated great potential in suppressing proliferation and metastasis of cancer cells, its anti-tumor activity can be promoted by combination therapy. Metformin, as an anti-diabetic agent, has been applied in cancer therapy, due to its capacity in inhibiting proliferation, metastasis, and induction of apoptosis, and cell cycle arrest [120,121]. It seems that combination therapy of breast cancer cells using chrysin and metformin exerts a synergistic effect and is more efficient compared to chrysin alone. Cyclin D1 and hTERT are down-regulated by chrysin and metformin in breast cancer therapy [122].

5.2. Lung Cancer

International Agency for Research on Cancer has considered nickel as one of the carcinogenic agents [123–125]. Exposing to nickel-containing compounds is correlated with the risk of lung cancer development [126,127]. Enhancing ROS levels, inflammation induction, epigenetic gene regulation, and stimulation of signaling pathways are positively affected by nickel in cancer development [128–130]. Furthermore, activation of toll-like receptors (TLRs) is associated with cancer development [131,132]. The nuclear factor-kappaB (NF-κB) signaling pathway promotes inflammation and cancer progression [133]. A report has evaluated and compared the efficiency of five natural products, including quercetin, chrysin, curcumin, apigenin, and luteolin. Among them, quercetin and chrysin demonstrated the highest efficacy in lung cancer treatment. A combination of quercetin and chrysin reduced levels
of pro-inflammatory factors, such as IL-1β, IL-6, TNF-α, and IL-10, via NF-κB down-regulation. Furthermore, chrysin and quercetin decreased expressions of Myd88 and TLR4, as well as MMP-9, to suppress the viability and metastasis of lung cancer cells [134].

5.3. Prostate Cancer

Prostate cancer (PC) is one of the most common cancers in men that is responsible for 21% of cancer cases and 8% of cancer-related deaths in the United States [135–137]. Chemotherapy, radiotherapy, and prostatectomy are strategies in PC therapy, but recurrence and resistance of PC cells are problems, requiring novel strategies in PC therapy [138,139]. Increasing evidence demonstrates that PI3K/Akt and MAPK signaling pathways account for an increase in proliferation and metastasis of cancer cells, and their inhibition is important in cancer therapy [140–143]. In PC cells, chrysin down-regulates the expression of the PI3K/Akt pathway to interrupt the proliferation of PC cells. Furthermore, MAPK down-regulation by chrysin leads to a decrease in PC proliferation. Chrysin is able to induce apoptosis in PC cells via mitochondrial dysfunction, so that after chrysin administration, an increase occurs in levels of ROS that, subsequently, impairs the integrity of the mitochondrial membrane, leading to cytochrome C release and apoptosis induction [144]. Noteworthy, in addition to mitochondria, ER can also participate in apoptosis. The primary role of ER is to preserve cell homeostasis and ensuring the correct conformation of proteins. ER stress occurs when levels of unfolded proteins exceed from the capacity of ER. This leads to the activation of unfolded protein response (UPR) that, subsequently, stimulates PRKR-like ER kinase (PERK), eukaryotic translation initiation factor 2α (eIF2α), and 78 kDa glucose-regulated protein (GRP78) [145–148]. Chrysin administration also impairs ER homeostasis to induce ER-mediated apoptosis in PC cells [144].

5.4. Ovarian Cancer

Ovarian cancer (OC) is the fifth leading cause of death in women, and is considered one of the most lethal gynecologic cancers [135,149]. Based on the experiments performed in the field of OC treatment, it seems that phytochemicals are potential therapeutic agents in this case [150,151]. In the previous section, we discussed that mitochondrial dysfunction leads to apoptosis induction [152]. Upon chrysin administration, an increase occurs in levels of ROS and cytoplasmic Ca^{2+} that mediate apoptosis induction in OC cells [153]. However, this study provides controversial results about the role of molecular pathways that needs to be explored in further studies. Accumulating data demonstrates that the PI3K/Akt signaling pathway contributes to cancer proliferation and metastasis. PI3K/Akt inhibition has been suggested in different experiments as a promising strategy in cancer therapy [154–156]. However, a previous study has shown that chrysin suppresses OC malignancy via PI3K/Akt and MAPK induction [153]. Therefore, further studies are required to shed some light on this area.

5.5. Gastric Cancer

Gastric cancer (GC) is the third leading cause of cancer death, with 783,000 deaths in 2018 [157–160]. Different factors are involved in GC progression, and ten-eleven translocation (TET) enzyme is one of them. TET enzymes contribute to the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and participate in epigenetic modification [161]. Studies show the role of TET enzymes in GC development. For instance, TET1-mediated demethylation stimulates the aggressive behavior of GC cells [162]. TET2 exerts RASSF1A methylation to affect malignant cell activity [163]. Furthermore, down-regulation of TET3 has been shown in GC [164]. The effect of chrysin on GC cells has been investigated in vitro and in vivo. In MKN45 cells, chrysin promotes the expression of TET1 and 5hmC to stimulate apoptosis and disrupt migration and invasion of GC cells. Furthermore, TET1 deletion by CRISPR/Cas9 system in a mouse model leads to the development of GC, and chrysin administration can be considered as a promising strategy in GC suppression [165].
One of the properties of phytochemicals is their capability to regulate microRNA (miR) expression \cite{166,167}. Briefly, miRs are non-coding parts of the genome that are not transcribed into protein \cite{168}. Cellular mechanisms, such as proliferation, migration, differentiation, etc., are tightly regulated by miRs \cite{169}. Disturbance in miR expression leads to the emergence of pathological conditions, particularly cancer \cite{170,171}. Chrysin is capable of promoting the expression of miR-9 and Let-7a as onco-suppressor factors in cancer to inhibit the proliferation of GC cells. Using nanoparticles can significantly promote the ability of chrysin in enhancing miR-9 expression \cite{172}.

5.6. Cervical Cancer

Cervical cancer is one of the most common malignancies diagnosed in women \cite{173–175}. Chronic infection with high-risk human papillomavirus and inherited polymorphism of cytokine genes are involved in cervical cancer emergence \cite{176–180}. Hence, enhanced levels of cytokines participate in cervical cancer progression. Furthermore, EMT-related metastasis provides a poor prognosis of patients with cervical cancer \cite{181}. Hence, anti-tumor compounds with a modulatory effect on inflammation can be beneficial in suppressing cervical cancer metastasis. Exposing cervical cancer cells into transforming growth factor-beta (TGF-\(\beta\)) is associated with enhanced levels of TNF-\(\alpha\), inflammation, and metastasis. As a consequence of inflammation, NF-\(\kappa\)B is activated that induces Twist/EMT axis in cervical cancer metastasis. Chrysin (5, 10 and 20 \(\mu\)M) suppresses the aggressive behavior of cervical cancer cells in a dose-dependent manner. Down-regulation of NF-\(\kappa\)B, and subsequent decrease in Twist/EMT are mediated by chrysin administration, negatively affecting cervical cancer metastasis \cite{182}.

Scutellaria discolor Colebr is a well-known medicinal plant species with therapeutic effects in treating different diseases \cite{183}. There have been efforts in revealing bioactive compounds in this plant that are responsible for its pharmacological activities, particularly cancer. It has been reported that chrysin is the major bioactive component of this plant that provides the anti-tumor activity against cervical cancer cells. Induction of cell cycle arrest and apoptosis via up-regulation of caspase-3, caspase-9, and Bax are mediated by chrysin. Moreover, chrysin impairs the proper function of mitochondria via providing mitochondrial membrane depolarization, leading to reduced viability of cervical cancer cells \cite{184}.

5.7. Liver Cancer

Studies are in line with the fact that cancer cells are different from normal cells in terms of metabolism \cite{185}. Aerobic glycolysis, or the Warburg effect, is one of the hallmarks of cancer that was first recognized in 1920 by Otto Heinrich Warburg \cite{186}. In this process, regardless of oxygen levels, glucose is converted into lactate to meet the needs of cancer cells into energy, leading to their uncontrolled proliferation \cite{187}. Different factors have been recognized to participate in changing the metabolism of cancer cells from the Krebs cycle to glycolysis, and hexokinases (HKs) are one of them \cite{188,189}. A large body of evidence shows the important role of HK-2 in the Warburg effect in different cancers \cite{190–193}. Chrysin administration (15, 30, and 60 mM) reduces the expression of HK-2 in hepatocellular carcinoma (HCC) cells to impair glucose uptake and lactate production. In addition to glycolysis metabolism impairment, the inhibitory effect of chrysin on HK-2 leads to apoptosis, so that chrysin disrupts the interaction of HK-2 and VDAC-1 on mitochondria that releases Bax from mitochondrial into the cytoplasm, leading to apoptosis induction. Notably, tumor xenografts treated with chrysin demonstrated a decrease in HK-2 levels in tissues \cite{194}.

The main pathway that is followed by chrysin in suppressing liver cancer survival is apoptosis induction. In this way, chrysin substantially enhances levels of ROS that, subsequently, disturbs mitochondrial function. Disruption in the integrity of the mitochondrial membrane leads to cytochrome C release into the cytoplasm, resulting in apoptotic cell death \cite{195}.

Increasing evidence is in agreement with the fact that the STAT3 signaling pathway participates in the proliferation and invasion of HCC cells \cite{196–199}. Inhibition of STAT3 by anti-cancer agents is important in effective HCC therapy \cite{200–202}. In HCC cells exposed to chrysin, a decrease occurs
in sphere formation capacity. Investigation of molecular pathways reveals that STAT3 undergoes down-regulation upon chrysin administration. Notably, an upstream modulator of STAT3 known as SHP-1 is up-regulated by chrysin, and consequently, it decreases expression of STAT3, leading to inhibited sphere formation [203].

5.8. Melanoma

Melanoma is a highly resistant and malignant tumor of the skin that is responsible for about 3% of all cancer cases. Over the past decades, we have witnessed an increase in the occurrence of melanoma. Although melanoma accounts for 4% of all skin cancer cases, its aggressiveness and malignancy have led to comprising 80% of all deaths from skin cancer [204]. Melanoma, at the first stages, can be treated with surgery, but in an advanced stage, it metastasizes into other sites, making its treatment more complex [205–207]. Plant derived-natural compounds can be considered as potential agents in melanoma therapy, due to their ability in apoptosis and cell cycle induction, and inhibiting migration [208–210]. Chrysin is a potent agent in melanoma therapy, and this ability has been approved in vitro and in vivo. Chrysin stimulates apoptosis and cell cycle arrest (G2/M phase) in a dose-dependent manner. In tumor xenografts, chrysin decreases tumor growth by 60% after 14 days of treatment, while this number enhances to 70% after 21 days of treatment. Noteworthy, in melanoma therapy, chrysin promotes cytotoxicity activity of natural killer cells, macrophages, and cytotoxic T cells [211].

MMPs are involved in enhancing the invasion of cancer cells via extracellular matrix (ECM) degradation [212,213]. MMP-2 and MMP-9 provide metastasis of cancer cells into distant organs via degrading matrix collagen and basement membrane [214,215]. Chrysin (5–15 µM) suppresses metastasis of melanoma cells via down-regulation of MMP-2. Furthermore, N-cadherin and E-cadherin are respectively down-regulated and up-regulated upon chrysin administration in inhibiting melanoma invasion [182]. In previous sections, we discussed the oncogene role of NF-κB and PI3K/Akt signaling pathways in cancer. Chrysin treatment is associated with a decrease in expression of NF-κB and PI3K/Akt to suppress melanoma proliferation [182].

5.9. Bladder Cancer

The second most common type of tract cancer in developed countries is bladder cancer. Its incidence rate is around 400,000 cases, with approximately 160,000 death annually [135]. Chemotherapy is not suggested in bladder cancer therapy, due to side effects and chemoresistance [216]. Novel strategies can be developed for promoting the efficacy of chemotherapy in bladder cancer therapy, such as using phytochemicals with anti-tumor activity [217,218]. On the other hand, molecular pathways, such as STAT3 participate in bladder cancer progression [219]. STAT3 can individually promote the proliferation of bladder cancer cells [220], or it may be targeted by upstream mediators, such as Akt/ERK [221]. Administration of chrysin is correlated with an increase in ROS levels to down-regulate STAT3 expression. Furthermore, chrysin activates the intrinsic pathway of apoptosis via caspase-3 and caspase-9 up-regulation. Anti-apoptotic factors, such as Bcl-2, Mcl-1, and Bcl-xL undergo down-regulation by chrysin in bladder cancer cells. Notably, chrysin substantially diminishes survival by ER stress induction via stimulating UPR, PERK, ATF4, and eIF2α [222].

5.10. Colorectal Cancer

Colorectal cancer (CRC) is a heterogeneous disease with a rise in the incidence rate in recent years. Both molecular and pathological properties determine the prognosis and response of CRC cells into therapy [223,224]. 5-fluorouracil (5-FU) is extensively applied in treating patients with CRC, but drug resistance and side effects have restricted its use [225,226]. Recently, chrysin has been considered as a substitution for 5-FU in CRC therapy. Chrysin administration (5–50 µM) is associated with a significant decrease in the viability of CRC cells [227]. An investigation into the molecular mechanisms demonstrates that autophagy is affected by chrysin in CRC therapy. Autophagy is a “self-digestion” process with stimulation upon stressful conditions, such as ER stress, mitochondrial damage, starvation,
etc. [228, 229]. Autophagic cell death is important in reducing the viability of cancer cells [230, 231]. Chrysin enhances levels of light chain-3 II (LC-3II) to induce autophagy. Furthermore, by promoting ROS generation, chrysin down-regulates the expression of the mammalian target of rapamycin (mTOR) to stimulate autophagy, leading to a decrease in the viability of CRC cells [227].

It is worth mentioning that irradiation can improve the anti-tumor activity of chrysin against colon cancer cells. Irradiation technology is able to promote biological properties or physical features of biomolecules through structural modification [232–234]. Recently, chrysin and gamma irradiation have been co-applied in colon cancer therapy. Irradiation substantially enhances the cytotoxic activity of chrysin. This inhibitory effect against colon cancer cells is exerted via promoting ROS generation, inducing mitochondrial dysfunction, activation of a caspase cascade (caspase-3 and caspase-9), and stimulating cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP) [235].

Peroxisome proliferator-activated receptor alpha (PPARα) is a crucial member of the superfamily of nuclear hormone receptors with regulatory effects on migration, proliferation, metabolism, etc. [236–239]. Increasing evidence demonstrates that using a specific ligand for stimulation of PPARα is of interest in suppressing cancer growth [240, 241]. On the other hand, cytochrome P450 (CYPs) enzymes contribute to drug metabolism and are found in different organs of the body, such as lung, liver, etc. [242, 243]. PPARα is able to regulate gene expression of CYPs, such as CYP3A4 and CYP2C8 [244]. Chrysin administration significantly enhances the expression of PPARα in cancer cells. This leads to a significant reduction in expression of CYP2S1 and CYP1B1, leading to decreased proliferation (cell cycle arrest) and migration of cancer cells [245].

A schematic summary on anti-tumor effects of chrysin in cancer is shown in Figure 3. Table 2 list chrysin administration in treating various cancers.

**Figure 3.** Mechanisms involved in the anti-tumor activity of chrysin against different cancers. IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; NF-κB, nuclear factor-kappaB; ROS, reactive oxygen species; ER, endoplasmic reticulum; Mcl-1, myeloid cell leukemia-1; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; miR, microRNA; MMP, matrix metalloproteinase; TLR4, toll-like receptor 4; mTOR, mammalian target of rapamycin.
Table 2. Chrysin administration in treating various cancers.

| Cancer Type       | In Vitro/In Vivo | Cell Line/Animal Model                                      | Dose (In Vivo)/Concentration (In Vitro) | Period of Experiment | Administration Route | Outcomes                                                                                                                                                                                                 | Refs |
|-------------------|------------------|-------------------------------------------------------------|----------------------------------------|----------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Prostate cancer   | In vitro         | DU145 and PC-3 cell lines                                   | 12.5, 25 and 50 µM                    | -                    | -                    | Induction of mitochondrion- and ER-mediated apoptosis Cell cycle arrest Down-regulation of MAPK and PI3K/Akt signaling pathways Impairing proliferation of PC cells                                                                 | [144]|
| Gastric cancer    | In vitro         | MKN45 cells Mouse model of GC (created by CRIPSR/Cas9)     | 10, 20, 40, 80 and 160 µM 20 mg/kg    | 12, 24 and 45 h 14 days | Oral gavage          | Suppressing migration Apoptosis induction Enhancing TET1 expression                                                                                                                                 | [165]|
| Lung cancer       | In vitro         | A549 cells                                                  | 2 and 5 µM                            | 4 h                  | -                    | Down-regulation of MyD88 and TLR4 Inhibition of inflammation via NF-κB down-regulation Suppressing survival and metastasis                                                                 | [134]|
| Cervical cancer   | In vitro         | HeLa cells                                                  | 5, 10, 20 and 40 µM                  | 0.5, 3, 6, 12 and 24 h | -                    | Down-regulation of NF-κB signaling pathway Inhibition of Twist/EMT axis Suppressing metastasis of cervical cancer                                                                                       | [182]|
| Breast cancer     | In vitro         | T47D breast cancer cells                                    | 20, 40, 60, 80, 100 and 120 µM       | 48 h                 | -                    | Disrupting proliferation of cancer cells via down-regulation of cyclin D1 and hTERT                                                                                                                  | [105]|
| Hepatocellular    | In vitro/In vivo | Normal human hepatic cell LO2 and HepG2, Hep3B, Huh-7, HCC-LM3, Bel-7402 and SMMC-7721 Tumor xenografts | 15, 30, and 60 µM 30 mg/kg           | 24, 48 and 72 h Intraperitoneal injection | -                    | Down-regulation of HK-2 Suppressing glycolysis Apoptosis induction                                                                                                                                   | [194]|
| Breast cancer     | In vitro         | HeLa cells                                                  | 15, 20, 25 and 30 µM                 | 30 min               | -                    | Significant reduction in survival of cancer cells Inducing both intrinsic and extrinsic apoptotic pathways P53-dependent apoptosis                                                                           | [246]|
| Ovarian cancer    | In vitro         | SKOV3 cell line                                             | 5, 10 and 20 µmol/L                  | -                    | -                    | Decreasing the viability of cancer cells in a dose-dependent manner Down-regulation of CK2α, CD133 and CD44 Suppressing sphere formation capability                                                          | [247]|
| Breast cancer     | In vitro         | MDA-MB-231                                                  | 10 µM                                 | 24 and 48 h          | -                    | Inhibition of EGFR Reducing migration, growth and sphere formation ability of cancer cells                                                                                                              | [109]|

**Table 2.** Chrysin administration in treating various cancers.
Table 2. Cont.

| Cancer Type         | In Vitro/In Vivo | Cell Line/Animal Model                                                                 | Dose (In Vivo)/Concentration (In Vitro) | Period of Experiment | Administration Route | Outcomes                                                                                      | Refs     |
|---------------------|------------------|----------------------------------------------------------------------------------------|----------------------------------------|---------------------|---------------------|---------------------------------------------------------------------------------------------|----------|
| Breast cancer       | In vitro         | 4T1 mouse breast cancer cells Balb/c mice implanted with 4T1 cells                     | 60–100 μM 250 mg/kg                   | 30 min 18 days      | Oral administration | Suppressing lung metastasis Down-regulation of VEGF, and STAT3 Inhibiting proliferation   | [119]    |
| Prostate cancer     | In vitro         | Human prostate cancer cell line PC-3                                                   | 10, 20, 30, and 40 μM                 | 24, 48 and 72 h     | -                   | Reducing the viability of cancer cells in a time- and dose-dependent manner Apoptosis induction | [248]    |
| Cervical cancer     | In vitro         | Human cervical epidermoid carcinoma cell line ME180, and human cervical carcinoma cell lines HeLa, BU25TK- and SiHa | 0–160 mg/mL                           | -                   | -                   | Apoptosis induction via caspase-3, caspase-9, and Bax up-regulation Stimulating mitochondrial dysfunction Cell cycle arrest induction | [184]    |
| Liver cancer        | In vitro         | Hepatocellular carcinoma cells                                                         | 5–100 μM                               | 15, 30, 45 and 60 min | -                   | Mitochondrial dysfunction Cytochrome c release into the cytoplasm Apoptosis induction      | [195]    |
| Breast cancer       | In vitro         | MDA-MB-231 and MCF-7 cells                                                            | 3–12 μM                                | -                   | -                   | Reducing the viability of cancer cells Apoptosis induction via caspase-3 and caspase-7 up-regulation | [249]    |
| Melanoma            | In vitro         | B16F10 cells Melanoma-bearing mice                                                     | 12.5, 25, 50, and 100 μM 50 mg/kg     | 24 and 48 h 21 days | -                   | Induction of cell cycle arrest at G2/m phase Reducing tumor growth in vivo Promoting the anti-tumor activity of immune cells, such as macrophages and natural killer cells | [211]    |
| Oral squamous cell carcinoma | In vitro | Oral squamous carcinoma KB cell line                                                  | 1, 2, 4, 8, 16, and 32 μmol/L         | 24 h                | -                   | Suppressing proliferation in a dose-dependent manner Apoptosis induction via caspase-3 and caspase-7 up-regulation Inducing mitochondrial dysfunction Reducing the viability via down-regulation of PI3K/Akt signaling pathways | [250]    |
| Bladder cancer      | In vitro         | Human bladder cancer cell lines T-24 and 5637 and the non-malignant immortalized urothelial SV-HUC-1 cells | 20, 40 and 80 μM                      | 24 h                | -                   | Induction of ER stress via UPR activation Stimulating intrinsic pathway of apoptosis via caspase-3 and caspase-9 up-regulation Inhibition of STAT3 signaling pathway | [251]    |
| Cancer Type          | In Vitro/ In Vivo | Cell Line/Animal Model                  | Dose (In Vivo)/ Concentration (In Vitro) | Period of Experiment | Administration Route | Outcomes                                                                 | Refs |
|---------------------|-------------------|----------------------------------------|------------------------------------------|----------------------|----------------------|---------------------------------------------------------------------------|------|
| Melanoma            | In vitro          | Human melanoma A375.S2 cell line       | 5, 10 and 15 µM                          | 24 and 48 h          | -                    | Impairing metastasis via VEGF, MMP-2, and N-cadherin down-regulation     | [182]|
|                     |                   |                                        |                                          |                      |                      | Enhancing E-cadherin expression                                           |      |
|                     |                   |                                        |                                          |                      |                      | Down-regulation of PI3K/Akt and NF-kB pathways in suppressing cancer proliferation |      |
| Colorectal cancer   | In vitro          | SW48, SW480, and SW620 CRC cells       | 5–50 µM                                 | 24 h                 | -                    | Enhancing ROS generation mTOR down-regulation                             | [227]|
|                     |                   |                                        |                                          |                      |                      | Elevating LC-3II levels                                                  |      |
|                     |                   |                                        |                                          |                      |                      | Autophagy induction                                                      |      |
|                     |                   |                                        |                                          |                      |                      | Impairing cancer cell viability                                           |      |
| Breast cancer       | In vitro          | MCF-7 cells                            | 20 and 30 µM                            | 48 and 72 h          | -                    | Anti-proliferative activity in a dose- and time-dependent manner          | [252]|
|                     |                   |                                        |                                          |                      |                      | Apoptosis induction                                                      |      |
| Cervical cancer     | In vitro          | HeLa cells                             | 0–10 µM                                 | 12–48 h              | -                    | Stimulating apoptosis and cell cycle arrest                               | [253]|
|                     |                   |                                        |                                          |                      |                      | Down-regulation of COX-2 expression                                       |      |
| Colon cancer        | In vitro          | HT-29 cells                            | 12.5, 25, 50, and 100 µg/mL             | -                    | -                    | Induction of apoptosis via mitochondrial dysfunction                       | [235]|
|                     |                   |                                        |                                          |                      |                      | Irradiation combined with chrysirin exerts a synergistic effect           |      |
| Thyroid carcinoma   | In vitro          | HTh7 and KAT18 cells                   | 25, 50, and 75 µM 75 mg/kg              | 2–6 days 21 days     | Oral gavage           | Reducing the viability and growth via up-regulation of Notch1 and its down-stream target, Hes1 | [254]|
| Hepatocellular      | In vitro          | SMMC-7721 cells                        | 10, 20 and 40 µM                        | 24 and 48 h          | -                    | Reducing sphere formation via STAT3 down-regulation                       | [203]|
| Breast cancer       | In vitro          | MCF-7 cells                            | 40 µM                                    | 8 h                  | -                    | Decreasing cell viability by p53 activation through ATM-Chk2 axis         | [255]|
|                     |                   |                                        |                                          |                      |                      | Lack of DNA damage                                                       |      |
| Tongue squamous cell carcinoma | In vitro | CAL-27 cells                          | 5, 25, 55 and 80 µM                     | 24 h                 | -                    | Apoptosis induction via caspase-3 and caspase-9 up-regulation             | [256]|
| Choriocarcinoma cells | In vitro      | JAR and JEG3 cells                    | 0–100 µM                                | 24 h                 | -                    | Suppressing cell viability in a dose-dependent manner                     | [257]|
|                     |                   |                                        |                                          |                      |                      | Inducing cell death via promoting ROS production and changing mitochondrial membrane potential |      |
| Cancer Type     | In Vitro/In Vivo | Cell Line/Animal Model | Dose (In Vivo)/Concentration (In Vitro) | Period of Experiment | Administration Route | Outcomes                                                                 | Refs  |
|----------------|------------------|------------------------|----------------------------------------|----------------------|----------------------|--------------------------------------------------------------------------|-------|
| Colorectal cancer | In vitro         | HCT116 cells           | 20, 30, 40 and 50 µM                   | 36 h                 | -                    | Cell cycle arrest, Migration inhibition, PARPα up-regulation, CYP2S1 and CYP1B1 induction | [245] |
| Colon cancer    | In vitro/In vivo  | CT26 cells Allograft colon carcinoma model | 10–200 µg/mL 0–10 mg/kg | 24 and 48 h 28 days | Oral administration  | Reducing tumor growth, Induction of apoptosis via caspase-3 and caspase-9 up-regulation | [258] |
6. Chrysin, Chemotherapy and Drug Resistance

Chemotherapy is an inevitable part of cancer therapy, but its potential has been restricted in recent years, due to the resistance of cancer cells [259,260]. In fact, chemoresistance of cancer cells has urged scientists to seek new anti-tumor agents [261]. Based on the role of natural products in cancer treatment, they can be beneficial in sensitizing cancer cells into chemotherapy [262,263]. That is why these valuable agents have been extensively co-administered with chemotherapeutic agents in cancer therapy. Anti-tumor phytochemicals can suppress proliferation, metastasis, and malignant behavior of cancer cells that are in favor of chemotherapeutic agents [102,264,265]. In this section, we provide a discussion about the role of chrysin as a naturally occurring compound in reversing drug resistance.

Cisplatin is a well-known chemotherapeutic agent with clinical application. However, resistance is the most important reason for treatment failure with this agent in the clinic [266,267]. Various molecular pathways have been suggested to participate in cisplatin resistance, such as CLEC4M, miRs, IncRNAs, etc. [268,269]. In respect to the high anti-tumor activity of chrysin, this plant derived-natural compound can be advantageous in suppressing chemoresistance. Noteworthy, it has been reported that selenium-containing chrysin and quercetin derivatives are potent agents in reversing cisplatin resistance [270].

Docetaxel (DTX) is a commercially applied chemotherapeutic agent in treating lung cancer, breast cancer, gastric cancer, etc. DTX stimulates apoptosis and cell cycle arrest via attaching β-tubulin into microtubules and disrupting cancer growth [271]. Similar to other chemotherapeutic agents, cancer cells are capable of obtaining resistance to DTX [272]. Moreover, the anti-tumor activity of DTX can be improved by combinational therapy [273]. A combination of chrysin (20–100 µM) and DTX is advantageous in suppressing the proliferation of cancer cells, and inducing growth delay in tumor xenografts [274]. This is distributed to apoptosis induction by chrysin that, subsequently, sensitizes cancer cells into DTX chemotherapy [274].

P53 is a key player in apoptosis induction. It stimulates apoptosis in both transcription-dependent and transcription-independent manners. In the transcription-dependent pathway, down-stream genes of p53 are regulated to induce apoptosis in cancer cells [275–277]. Furthermore, p53 is capable of moving out of the nucleus, and interacting with mitochondria and its proteins, such as Bcl-2 and Bcl-xl, in apoptosis induction [278]. In liver cancer cells exposed to chrysin and cisplatin, an increase occurs in phosphorylation and accumulation of p53 via ERK1/2 up-regulation. Consequently, apoptotic factors, such as Bax and DR5, undergo up-regulation, while a decrease occurs in the expression of anti-apoptotic factor Bcl-2. The intrinsic pathway of apoptosis is activated via caspase-8 activation. Chrysin and cisplatin also induce the extrinsic pathway of apoptosis via releasing cytochrome C into the cytoplasm and activating caspase-9 [279].

Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important signaling pathway involved in antioxidant activity against oxidative stress and other kinds of stresses [280–282]. Recently, much attention has been directed towards the role of Nrf2 in the chemoresistance of cancer cells [283]. Nrf2 follows different routes in exerting chemoresistance, such as enhancing expression of CD99 [284], inhibiting DNA damage [285], and reducing oxidative stress-mediated damage [286]. Therefore, Nrf2 inhibition is important in reducing chemoresistance. Chrysin administration (10 and 20 mM) promotes the sensitivity of cancer cells into doxorubicin chemotherapy. Further analysis reveals that Nrf2 undergoes down-regulation by chrysin in cancer cells. Furthermore, in reducing Nrf2 expression, chrysin down-regulates the expression of ERK and PI3K/Akt pathways—leading to an increase in the efficiency of doxorubicin in chemotherapy [287].

7. Chrysin-Loaded Nanoparticles in Cancer Therapy

Micelles have attracted much attention in cancer therapy, due to their potential to deliver anti-tumor agents [288,289]. Self-assembled micelles are amphiphilic copolymers with size at the range of 10–100 nm. Micelles have high cellular uptake and passive targeting functions to tumor known as enhanced permeability [290,291]. Recently, chrysin- and docetaxel-loaded micelles have been
applied in enhancing the efficacy of chemotherapy. This co-delivery by micelles exerts a synergistic effect on chemotherapy and effectively suppresses migration and invasion of cancer stem cells. Chrysin- and docetaxel-loaded micelles enhance levels of ROS to impair cancer stem cell viability. Notably, enhanced the anti-tumor activity of chrysin and docetaxel against cancer cells is due to their enhanced accumulation in cancer cells by micelles [292]. Polymeric micelles have also been designed in co-delivery of chrysin and methotrexate in the chemotherapy of breast cancer cells. The idea of using a chemotherapeutic agent with a natural anti-tumor agent is that this combination is important in sensitizing cancer cells into chemotherapy. Using nanoparticles promotes cytotoxicity against cancer cells via enhancing cellular uptake. Based on the small size of polymeric micelles (around 55 nm), they can escape from macrophages and kidney filtration to reach into the tumor site, providing targeted delivery of anti-tumor compounds [293].

Another study has applied polyurea dendrimers for delivery of chrysin in ovarian cancer therapy. Polyurea dendrimers are three-dimensional polymers with urea moieties in the backbone and peripheral amine groups. They possess various beneficial properties, including water-solubility, biocompatibility, biodegradability, and pH-sensitivity, making them suitable options in drug delivery [294]. Furthermore, as cancer cells overexpress folate receptors on their surface [295,296], surface functionalization of nanoparticles with folate can be advantageous in enhancing cellular uptake of these nanoparticles and providing selective targeting. Chrysin- and selenium-loaded dendrimers are capable of induction of oxidative stress and reducing the viability of OC cells. Furthermore, they demonstrate no toxicity against normal cells that can be attributed to using folate for the functionalization of dendrimers [297].

Polymeric nanoparticles possess a core-shell structure that self-assemble in an aqueous medium. The hydrophilic shell is responsible for preserving the stability of nanoparticle, and the hydrophobic core encapsulates anti-tumor drug. Synthetic polymers, including poly (e-caprolactone) (PCL), polyglycolide (PGA), and polylactides (PLA), are applied in biomedical applications, due to their features, such as biocompatibility, high permeability, predictable degradation kinetics, etc., that are important in the field of biomedicine [298–300]. However, crystallinity and low biodegradation are drawbacks of PCL that can be solved using monomers. Poly (ethylene glycol) (PEG) is a safe, flexible, and hydrophilic agent approved by the Food and Drug Administration (FDA) that can be used internally in the human body [298,301–303]. Chrysin-loaded polymeric nanoparticles have been applied in breast cancer therapy. The results demonstrate that targeted delivery of chrysin at the tumor site by polymeric nanoparticles leads to enhanced anti-tumor activity, due to enhanced cellular uptake [304].

Nanoparticles can provide a platform for co-loading of chrysin with other natural anti-tumor compounds, such as curcumin. Briefly, curcumin is isolated from the rhizome of curcuma longa and has potent anti-tumor activity against different cancer cells [305]. Using nanoparticles can significantly enhance the bioavailability and therapeutic effects of curcumin [306]. Curcumin- and chrysin-loaded PLGA-PEG nanoparticles have been designed in CRC therapy. This co-loading exerts a synergistic effect and enhances the cytotoxicity of these phytochemicals against CRC cells [307]. Studies demonstrate that telomerase activity is associated with enhanced proliferation and invasion of cancer cells. Catalytic domain (hTERT) participates in telomerase gene overexpression that has been reported in CRC [308,309]. Chrysin- and curcumin-loaded nanoparticles effectively down-regulate the expression of hTERT in suppressing the progression of CRC cells [307]. In addition to the anti-proliferative activity via hTERT down-regulation, chrysin- and curcumin-loaded nanoparticles can suppress metastasis of cancer cells via reducing expressions of MMP-2 and MMP-9 [310].

Several homologous proteins known as tissue inhibitors of metalloproteinase (TIMPs) can regulate the activity of MMP’s. TIMP-1 and TIMP-2 are capable of reducing the expression of MMP-2 and MMP-9 in suppressing metastasis and migration of cancer cells [311]. Chrysin- and curcumin-loaded nanoparticles significantly promote the expression of TIMP-1 and TIMP-2 to exert a reduction in melanoma invasion [310]. Taking everything into account, studies agree with the fact that nanoparticles can enhance the anti-tumor activity of chrysin against cancer cells [62,312–316]. Nanoparticles can provide a platform for the co-delivery of chrysin and other anti-tumor agents that is important in
promoting its inhibitory effect against cancer cells (Figure 4) (Table 3). Further studies can focus on developing other types of nanocarriers, such as carbon nanotubes, liposomes, etc., for delivery of chrysin in cancer therapy.

![Figure 4. Chrysin-loaded nanoparticles in cancer therapy.](image-url)
### Table 3. Chrysin-loaded nanoparticles in cancer therapy.

| Nanovehicle       | Cancer Type | In Vitro/In Vivo | Cell Line/Animal Model                                                                 | Particle Size (nm) | Zeta Potential (mV) | Encapsulation Efficiency (%) | Outcomes                                                                 | Refs |
|-------------------|-------------|-----------------|----------------------------------------------------------------------------------------|--------------------|----------------------|------------------------------|--------------------------------------------------------------------------|------|
| Micelle           | Colorectal cancer | In vitro | Human-derived epithelial colorectal cancer cell lines HT-29                            | 72–142             | +10.1                | 77 (Docetaxel) 44 (chrysin) | Enhanced cellular uptake Effective inhibition of cancer stem cell migration | [292]|
| Polymeric micelles | Breast cancer | In vitro | MCF-7 cells                                                                           | 55                 | +2.7                 | 87.6 (methotrexate) 86.5 (chrysin) | Enhancing efficacy of chrysin and methotrexate in breast cancer therapy via promoting cellular uptake | [293]|
| Dendrimer         | Ovarian cancer | In vitro | Serous carcinoma (OSC) cell lines (OVCAR3 HTB-161™ and OVCAR8 CVCL_1629™) and a clear cell carcinoma (OCCC) cell line (ES2 CRL-1978™) | -                  | -                    | -                           | Selective targeting of cancer cells by folate functionalization of dendrimers High cellular uptake Remarkable decrease in survival of cancer cells | [297]|
| Polymeric nanoparticles | Breast cancer | In vitro | T47D breast cancer cell line                                                           | 75                 | -                    | 99.89                        | Higher cytotoxicity against breast cancer cells compared to chrysin alone | [304]|
| PLGA-PEG nanoparticles | Breast cancer | In vitro | T47-D breast cancer cell line                                                           | 20–75              | -                    | 70                           | High cytotoxicity Excellent cellular uptake and encapsulation efficiency | [317]|
| PLGA-PEG nanoparticles | Colorectal cancer | In vitro | SW480 cells                                                                            | 50–140 nm          | -                    | -                           | Higher cytotoxicity compared to chrysin and curcumin alone hTERT down-regulation | [307]|
| PLGA-PEG nanoparticles | Melanoma     | In vivo | C57B16 mice bearing B16F10 melanoma tumours                                            | 285                | −3.7                 | 78.27 (curcumin) 83.5 (chrysin) | Enhancing expression of TIMP-1 and TIMP-2 Down-regulation of MMP-2 and MMP-9 Suppressing metastasis of cancer cells | [310]|
| Solid lipid nanoparticles | Breast cancer | In vitro | MCF-7 cells                                                                            | Below 500          | −20 to −47           | More than 90%               | High stability and promoting the anti-tumor activity of chrysin          | [312]|
| PLGA-PEG nanoparticles | Breast cancer | In vitro | T47D cells                                                                             | 70–300             | -                    | 99.89                        | Accumulation in breast cancer cells High cytotoxicity                   | [318]|
| PLGA-PEG nanoparticles | Breast cancer | In vitro | MDA-MB-231 cells                                                                      | 305                | −3.8                 | 80.22 (curcumin) 85.25 (chrysin) | Synergistic effect Cell cycle arrest at G2/M phase Apoptosis induction Up-regulation of miR-132 and miR-502c | [319]|
| Copolymer nanoparticle | Lung cancer  | In vitro | A549 cells                                                                             | 77                 | −2.22                | 46.96                        | Enhanced cytotoxicity More potential in exerting tumor growth delay       | [320]|
| Micelle           | Breast cancer | In vitro | MCF-7 cells                                                                            | 152–420            | −21.6                | 52–89                        | Promoting bioavailability of chrysin Exerting a 5-fold increase in anti-tumor activity | [321]|
| PLGA-PEG nanoparticles | Gastric cancer | In vitro | AGS cells                                                                             | 70–300             | -                    | 98.6                         | Decreasing cell survival via down-regulation of miR-18a, miR-21, and miR-221 | [322]|
8. Conclusions and Remarks

In the present review, we provided a mechanistic review of chrysin and its underlying mechanisms for anti-tumor activity [323–325]. Noteworthy, chrysin derivatives have also shown potential anti-tumor activity [326–329], showing that future studies can focus on chemical modification of chrysin structure in improving its bioavailability, anti-tumor activity, etc. Although chemical modification is a promising strategy in promoting the anti-tumor activity of chrysin, it seems that nanoscale delivery systems, such as polymeric nanoparticles, liposomes, solid lipid nanoparticles, etc., can also be considered in promoting cellular uptake of chrysin and enhancing its anti-tumor activity.

Chrysin affects various molecular pathways and mechanisms in cancer therapy. Apoptosis is the most well-known target of chrysin in cancer therapy, and both intrinsic and extrinsic pathways of apoptosis are induced by chrysin in cancer cells. Disrupting homeostasis of mitochondria and ER are followed by chrysin in apoptosis induction in cancer cells. Autophagy is another programmed cell death that is activated by chrysin in cancer therapy. As autophagy has a dual role in cancer, meaning it may suppress cancer progression, or may function as a pro-survival factor in promoting the proliferation of cancer cells [330–333], much attention should be directed towards the regulation of autophagy by chrysin in cancer therapy. It has been reported that chrysin induces autophagy in cancer therapy, showing the anti-tumor role of autophagy. However, more studies will reveal a relationship between chrysin and autophagy in cancer therapy. In terms of molecular pathways, oncogenic ones, such as STAT3, NF-κB, and PI3K, that are involved in cancer growth and metastasis, are suppressed upon chrysin administration. MiRs are also potential targets of chrysin in cancer therapy that their expression is regulated. Noteworthy, since studies have shown that chrysin is capable of modulating the expression of miRs, further studies can focus on evaluating the effect of chrysin on other types of non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).

Another potential application of chrysin is in suppressing chemoresistance. One of the major challenges in the field of chemotherapy is the resistance of cancer cells into the inhibitory effect of currently applied chemotherapeutic agents. Chrysin induces apoptosis to sensitize cancer cells into chemotherapy. Moreover, molecular pathways, such as Nrf2, that induce chemoresistance, are suppressed via chrysin. Further studies can focus on revealing other molecular pathways, such as miRs in chemoresistance, and the role of chrysin in their regulation.

In fact, different aspects of cancer cells are affected by chrysin, including proliferation, metastasis, and chemoresistance. These inhibitory effects are mediated via affecting both molecular pathways and mechanisms that were comprehensively discussed in the main text. As poor bioavailability is one of the drawbacks of chrysin in cancer therapy, a section was allotted to examine the role of nanoparticles for promoting bioavailability and the therapeutic effects of chrysin in cancer therapy. It is worth mentioning that these results were based on in vitro and in vivo experiments. Further studies can focus on evaluating the role of chrysin in clinical studies, which is important for clinical translation of chrysin.

Author Contributions: A.P.K., A.Z. (Ali Zarrabi) and M.A. participated in the conceptualization. M.A. and A.P.K. contributed to critical editing of manuscript. Soft-ware works were performed by M.A. and A.Z. (Ali Zarrabi) Data acquisition was done by E.M. and H.A. All other authors participated in preparing first draft of manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research is funded by grants from the National Medical Research Council Singapore (grant number NMRC/OFIRG/0020/2016) to Kumar AP. The National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative to Cancer Science Institute of Singapore; National University of Singapore also supported Kumar AP for this research.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

ER  endoplasmic reticulum
ROS  reactive oxygen species
EMT  epithelial-to-mesenchymal transition
NAFLD non-alcoholic fatty liver disease
TNF-α  tumor necrosis factor-α
IL  interleukin
I/R  ischemic/reperfusion
PD  Parkinson’s disease
TBI  traumatic brain injury
Nrf2  nuclear factor erythroid 2-related factor 2
EGFR  epidermal growth factor receptor
VEGF  vascular endothelial growth factor
HIF-1  hypoxia-inducible factor-1
STAT3  signal transducer and activator of transcription 3
TLRs  toll-like receptors
NF-kB  nuclear factor-kappaB
PC  prostate cancer
UPR  unfolded protein response
PERK  PRKR-like ER kinase
elF2α  eukaryotic translation initiation factor 2α
GRP78  78 kDa glucose-regulated protein
OC  ovarian cancer
GC  gastric cancer
5mC  5-methylcytosine
5hmC  5-hydroxymethylcytosine
miR  microRNA
TGF-β  transforming growth factor-beta
HK  hexokinase
HCC  hepatocellular carcinoma
ECM  extracellular matrix
5-FU  5-Fluorouracil
CRC  colorectal cancer
LC-3II  light chain-3II
mTOR  mammalian target of rapamycin
PPARα  Peroxisome proliferator-activated receptor alpha
CYP  cytochrome C
DTX  docetaxel
FDA  Food and Drug Administration
TIMPs  tissue inhibitors of metalloproteinases
lncRNAs  long non-coding RNAs
circRNAs  circular RNAs

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [CrossRef] [PubMed]
2. Kuipers, E.J.; Grady, W.M.; Lieberman, D.; Seufferlein, T.; Sung, J.J.; Boelens, P.G.; van de Velde, C.J.; Watanabe, T. Colorectal cancer. Nat. Rev. Dis. Primers 2015, 1, 15065. [CrossRef] [PubMed]
3. Das, B.; Pal, B.; Bhuyan, R.; Li, H.; Sarma, A.; Gayan, S.; Talukdar, J.; Sandhya, S.; Bhuyan, S.; Gogoi, G.; et al. MYC Regulates the HIF2α Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells. Cancer Res. 2019, 79, 4015–4025. [CrossRef]
4. Fang, Z.; Li, T.; Chen, W.; Wu, D.; Qin, Y.; Liu, M.; Wu, G.; He, L.; Li, H.; Gu, H. Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c. *Exp. Cell Res.* 2019, 382, 111462. [CrossRef] [PubMed]

5. Banik, K.; Ranaware, A.M.; Harsha, C.; Nitesh, T.; Girisa, S.; Deshpande, V.; Fan, L.; Nawalade, S.P.; Sethi, G.; Kunnumakkara, A.B.; et al. Piceatannol: A natural stilbene for the prevention and treatment of cancer. *Pharmacol. Res.* 2020, 153, 104635. [CrossRef]

6. Yu, Y.; Wang, Y.; Xiao, X.; Cheng, W.; Hu, L.; Yao, W.; Qian, Z.; Wu, W.; Chang, W. MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1. *Biochem. Cell Biol.* 2019, 97, 563–570. [CrossRef]

7. Sheng, X.; Li, Y.; Li, Y.; Liu, W.; Lu, Z.; Zhan, J.; Xu, M.; Chen, L.; Luo, X.; Cai, G.; et al. PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics. *BMC Cancer* 2019, 19, 840. [CrossRef]

8. Weng, W.; Goel, A. Curcumin and colorectal cancer: An update and current perspective on this natural medicine. *Semin. Cancer Biol.* 2020. [CrossRef]

9. Yang, S.-F.; Weng, C.-J.; Sethi, G.; Hu, D.-N. Natural Bioactives and Phytochemicals Serve in Cancer Treatment and Prevention. *Evid.-Based Complement. Altern. Med.* 2013, 2013, 698190. [CrossRef]

10. Mishra, S.; Verma, S.S.; Rai, V.; Awasthee, N.; Chava, S.; Hui, K.M.; Kumar, A.P.; Challagundla, K.B.; Sethi, G.; Gupta, S.C. Long non-coding RNAs are emerging targets of phytochemicals for cancers and other chronic diseases. *Cell. Mol. Life Sci.* 2019, 76, 1947–1966. [CrossRef]

11. Hsieh, Y.-S.; Yang, S.-F.; Sethi, G.; Hu, D.-N. Natural Bioactives in Cancer Treatment and Prevention. *BioMed Res. Int.* 2015, 2015, 182835. [CrossRef] [PubMed]

12. Lišková, A.; Koklesova, L.; Samec, M.; Smejkal, K.; Samuel, S.M.; Varghese, E.; Abotaleb, M.; Biringer, K.; Kudela, E.; Danko, J.; et al. Flavonoids in Cancer Metastasis. *Cancers* 2020, 12, 1498. [CrossRef] [PubMed]

13. Wu, C.-S.; Wu, S.-Y.; Chen, H.-C.; Chu, C.-A.; Tang, H.-H.; Liu, H.-S.; Hong, Y.-R.; Huang, C.-Y.; Huang, G.-C.; Su, A.C.-L. Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. *J. Nutr. Biochem.* 2019, 74, 108227. [CrossRef]

14. Bolat, Z.B.; Islek, Z.; Demir, B.N.; Yilmaz, E.N.; Sahin, F.; Ucisik, M.H. Curcumin- and Piperine-Loaded Emulsomes as Combinational Treatment Approach Enhance the Anticancer Activity of Curcumin on HCT116 Colorectal Cancer Model. *Front. Bioeng. Biotechnol.* 2020, 8, 50. [CrossRef] [PubMed]

15. Zhao, R.; Du, S.; Liu, Y.; Lv, C.; Song, Y.; Chen, X.; Zhang, B.; Li, D.; Gao, S.; Cui, W.; et al. Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy. *Theranostics* 2020, 10, 3594–3611. [CrossRef]

16. Deng, S.; Shanmugam, M.K.; Kumar, A.P.; Yap, C.T.; Sethi, G.; Bishayee, A. Targeting autophagy using natural compounds for cancer prevention and therapy. *Cancer* 2019, 125, 1228–1246. [CrossRef]

17. Shanmugam, M.K.; Warrier, S.; Kumar, A.P.; Sethi, G.; Arfuso, F.; Shanmugam, S.W.M.K. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer. *Curr. Vasc. Pharmacol.* 2017, 15, 503–519. [CrossRef]

18. Dai, X.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. *Exp. Biol. Med.* 2015, 240, 760–773. [CrossRef]

19. Merarchi, M.; Sethi, G.; Shanmugam, M.K.; Fan, L.; Arfuso, F.; Ahn, K.S. Role of Natural Products in Modulating Histone Deacetylases in Cancer. *Molecules* 2019, 24, 1047. [CrossRef]

20. Kim, C.; Cho, S.K.; Kapoor, S.; Kumar, A.; Vali, S.; Abbasi, T.; Kim, S.-H.; Sethi, G.; Ahn, K.S. β-carboxyphellene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase. *Mol. Carcinog.* 2013, 53, 793–806. [CrossRef]

21. Zhang, Q.; Zhang, Z.-Y.; Du, H.; Li, S.-Z.; Tu, R.; Jia, Y.-F.; Zheng, Z.; Song, X.-M.; Du, R.-L.; Zhang, X.-D. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. *Cell Death Differ.* 2019, 26, 2300–2313. [CrossRef] [PubMed]

22. Lai, K.-C.; Chueh, F.-S.; Hsiao, Y.-T.; Cheng, Z.-Y.; Lien, J.-C.; Liu, K.-C.; Peng, S.-F.; Chung, J.-G. Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. *Toxicol. Appl. Pharmacol.* 2019, 382, 114734. [CrossRef] [PubMed]
23. Montazerabadi, A.; Beik, J.; Iraijirad, R.; Attaran, N.; Khaledi, S.; Ghaznavi, H.; Shakeri-Zadeh, A. Folate-modified and curcumin-loaded dendrimer magnetite nanocarriers for the targeted thermo-chemotherapy of cancer cells. *Artif. Cells Nanomed. Biotecnol.* 2019, 47, 330–340. [CrossRef] [PubMed]

24. Al-Attar, T.; Madhily, S.V. Targeted cancer treatment using a combination of siRNA-liposomes and resveratrol-electrospun fibers in co-cultures. *Int. J. Pharm.* 2019, 569, 118999. [CrossRef] [PubMed]

25. Lin, C.-C.; Chin, Y.-T.; Shih, Y.-J.; Chen, Y.-R.; Chung, Y.-Y.; Lin, C.-Y.; Hsiung, C.-N.; Whang-Peng, J.; Lee, S.; Lin, H.-Y.; et al. Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. *J. Dent. Sci.* 2019, 14, 255–262. [CrossRef]

26. Sundaram, M.K.; Raina, R.; Afroze, N.; Bajbouj, K.; Hamad, M.; Haque, S.; Hussain, A. Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells. *Biosci. Rep.* 2019, 39. [CrossRef]

27. Prasannan, R.; Kalesh, K.A.; Shanmugam, M.K.; Nachiyappan, A.; Ramachandran, L.; Nguyen, A.H.; Kumar, A.P.; Lakshmanan, M.; Ahn, K.S.; Sethi, G. Key cell signaling pathways modulated by zerumbone: Role in the prevention and treatment of cancer. *Biochem. Pharmacol.* 2012, 84, 1268–1276. [CrossRef]

28. Siveen, K.S.; Ahn, K.S.; Ong, T.H.; Shanmugam, M.K.; Li, F.; Yap, W.N.; Kumar, A.P.; Fong, C.W.; Tergaonkar, V.; Hui, K.M.; et al. Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. *OncoTarget* 2014, 5, 1897–1911. [CrossRef]

29. Siveen, K.S.; Mustafa, N.; Li, F.; Kannaiyan, R.; Ahn, K.S.; Kumar, A.P.; Chng, W.-J.; Sethi, G. Thymoquinone overcomes chemo-resistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. *OncoTarget* 2013, 5, 634–648. [CrossRef]

30. Wu, M.; Zhang, P. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. *Cancer Lett.* 2019, 469, 207–216. [CrossRef]

31. Kim, S.-H.; Yoo, E.-S.; Woo, J.-S.; Han, S.-H.; Lee, J.-H.; Jung, J.-H.; Kim, H.-J.; Jung, J.-Y. Antitumor and apoptotic effects of quercetin on human melanoma cells involving JNK/P38 MAPK signaling activation. *Eur. J. Pharmacol.* 2019, 860, 172568. [CrossRef] [PubMed]

32. Tewari, D.; Nabavi, S.F.; Nabavi, S.M.; Sureda, A.; Farooqi, A.A.; Atanasov, A.G.; Vacca, R.A.; Sethi, G.; Fimognari, C. Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention. *Pharmacol. Res.* 2017, 128, 366–375. [CrossRef] [PubMed]

33. Lee, J.H.; Chiang, S.Y.; Nam, D.; Chung, W.-J.; Lee, J.; Na, Y.-S.; Sethi, G.; Ahn, K.S. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. *Cancer Lett.* 2014, 345, 140–148. [CrossRef] [PubMed]

34. Patel, S.M.; Venkata, K.C.N.; Bhattacharryya, P.; Sethi, G.; Bishayee, A. Potential of neem (*Azadirachta indica* L.) for prevention and treatment of oncologic diseases. *Semin. Cancer Biol.* 2016, 40–41, 100–115. [CrossRef]

35. Ko, J.; Yang, M.H.; Back, S.H.; Nam, D.; Jung, S.H.; Ahn, K.S. Theacrine attenuates epithelial mesenchymal transition in human breast cancer MDA-MB-231 cells. *Phytother. Res.* 2019, 33, 1934–1942. [CrossRef]

36. Cheng, J.-T.; Wang, L.; Wang, H.; Tang, F.R.; Cai, W.; Sethi, G.; Xin, H.-W.; Ma, Z. Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition. *Cells* 2019, 8, 1178. [CrossRef]

37. Loh, C.-Y.; Chai, J.Y.; Tang, T.F.; Wong, W.; Sethi, G.; Shanmugam, M.K.; Chong, P.P.; Looi, C.Y. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. *Cells* 2019, 8, 1118. [CrossRef]

38. Yuan, L.; Zhou, M.; Huang, D.; Wasan, H.S.; Zhang, K.; Sun, L.; Huang, H.; Ma, S.; Shen, M.; Ruan, S. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial-mesenchymal transition via the AKT/CSK-β/Smad signaling pathway. *Mol. Med. Rep.* 2019, 20, 2783–2795. [CrossRef]

39. Lee, J.H.; Mohan, C.D.; Devisagiman, A.; Jung, Y.Y.; Rangappa, S.; Basappa, S.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A.; Garg, M.; et al. Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. *J. Adv. Res.* 2020. [CrossRef]

40. Lee, J.H.; Mohan, C.D.; Shanmugam, M.K.; Rangappa, S.; Sethi, G.; Siveen, K.S.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A.; Basappa, S.; et al. Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. *Biochimie* 2020, 175, 58–68. [CrossRef]

41. Aggarwal, V.; Tuli, H.S.; Kaur, J.; Aggarwal, D.; Parashar, G.; Parashar, N.C.; Kulkarni, S.; Kaur, G.; Sak, K.; Kumar, M.; et al. Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells. *Biomedicines* 2020, 8, 103. [CrossRef] [PubMed]
42. Shahzadi, I.; Ali, Z.; Baek, S.H.; Mirza, B.; Ahn, K.S. Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. *Biomedicines* **2020**, *8*, 126. [CrossRef] [PubMed]

43. Henamayee, S.; Banik, K.; Sailo, B.L.; Shabnam, B.; Harsha, C.; Srilakshmi, S.; Naidu, V.; Baek, S.H.; Ahn, K.S.; Kunnumakkara, A.B. Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties. *Molecules* **2020**, *25*, 2278. [CrossRef]

44. Hwang, S.T.; Um, J.-Y.; Chinnathambi, A.; Alharbi, S.A.; Narula, A.S.; Namjoshi, O.A.; Blough, B.E.; Ahn, K.S. Evodiamine Mitigates Cellulose Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells. *Molecules* **2020**, *25*, 1320. [CrossRef] [PubMed]

45. Naz, I.; Ramchandani, S.; Khan, R.A.; Yang, M.H.; Ahn, K.S. Anticancer Potential of Raddeanin A, a Natural Triterpenoid Isolated from *Anemone raddeana* Regel. *Molecules* **2020**, *25*, 1035. [CrossRef]

46. Pingili, R.; Pawar, A.K.; Challa, S.R.; Kodali, T.; Kopppula, S.; Toleti, V. A comprehensive review on hepatoprotective and nephroprotective activities of chrysin against various drugs and toxic agents. *Chem. Interact.* **2019**, *308*, 51–60. [CrossRef]

47. Angelopoulou, E.; Pyrgelis, E.-S.; Piperi, C. Neuroprotective potential of chrysin in Parkinson’s disease: Molecular mechanisms and clinical implications. *Neurochem. Int.* **2020**, *132*, 104612. [CrossRef]

48. Naz, S.; Imran, M.; Rauf, A.; Orhan, I.E.; Shariati, M.A.; Qaisrani, T.B.; Shah, Z.A.; Plygun, S.; Heydari, M.; et al. Chrysin: Pharmacological and therapeutic properties. *Life Sci.* **2019**, *235*, 116797. [CrossRef]

49. Nabavi, S.F.; Braidy, N.; Habtemariam, S.; Orhan, I.E.; Daglia, M.; Manayi, A.; Gortzi, O.; Nabavi, S.M. Neuroprotective effects of chrysin: From chemistry to medicine. *Neurochem. Int.* **2015**, *90*, 224–231. [CrossRef]

50. Pietta, P.-G. Flavonoids as Antioxidants. *J. Nat. Prod.* **2000**, *63*, 1035–1042. [CrossRef]

51. Xu, H.; Luo, J.; Huang, J.; Wen, Q. Flavonoids intake and risk of type 2 diabetes mellitus. *Medicine* **2018**, *97*, e0686. [CrossRef] [PubMed]

52. Bajgai, S.P.; Prachyawarakorn, V.; Mahidol, C.; Ruchirawat, S.; Kittakoop, P. Bioactive microconstituents and antioxidant properties of wild edible mushrooms from the island of Lesvos, Greece. *Food Chem. Toxicol.* **2013**, *55*, 378–385. [CrossRef]

53. Escuredo, O.; Silva, L.R.; Valêntão, P.; Seijo, M.C.; Andrade, P.B. Assessing Rubus honey value: Pollen and phenolic compounds content and antibacterial capacity. *Food Chem.* **2012**, *130*, 671–678. [CrossRef]

54. Hadjmohammadi, M.R.; Nazari, S.S.S.J. Separation optimization of quercetin, hesperetin and chrysin in honey by micellar liquid chromatography and experimental design. *J. Sep. Sci.* **2010**, *33*, 3144–3151. [CrossRef]

55. Canini, A.; Pichichero, E.; Cicconi, R.; Mattei, M.; Muzi, M.G. Acacia honey and chrysin reduce proliferation of melanoma cells through alterations in cell cycle progression. *Int. J. Oncol.* **2010**, *37*, 973–981. [CrossRef]

56. Kalogeropoulos, N.; Yanni, A.E.; Koutrotsios, G.; Aloupis, M. Bioactive microconstituents and antioxidant properties of wild edible mushrooms from the island of Lesvos, Greece. *Food Chem. Toxicol.* **2013**, *55*, 378–385. [CrossRef]

57. Balta, C.; Herman, H.; Boldura, O.; Gasca, J.; Rosu, M.; Ardelean, A.; Hermenean, A. Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. *Chem. Interact.* **2015**, *240*, 94–101. [CrossRef]

58. Mani, R.; Natesan, V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. *Phytochemistry* **2018**, *145*, 187–196. [CrossRef]

59. Galijatovic, A.; Otake, Y.; Walle, U.K.; Walle, T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. *Xenobiotica* **1999**, *29*, 1241–1256. [CrossRef]

60. Walle, T.; Otake, Y.; Brubaker, J.A.; Walle, U.K.; Halushka, P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. *Br. J. Clin. Pharmacol.* **2001**, *51*, 143–146.

61. Walle, T.; Otake, Y.; Brubaker, J.A.; Walle, U.K.; Halushka, P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. *Br. J. Clin. Pharmacol.* **2001**, *51*, 143–146.

62. Ferrado, J.B.; Perez, A.A.; Visentini, F.F.; Islan, G.A.; Castro, G.R.; Santiago, L.G. Formation and characterization of self-assembled bovine serum albumin nanoparticles as chrysin delivery systems. *Colloids Surf. B Biointerfaces* **2019**, *173*, 43–51. [CrossRef] [PubMed]

63. Belhan, S.; Yildirim, S.; Karasu, A.; Kömüröglu, A.U.; Özdek, U. Investigation of the protective role of chrysin within the framework of oxidative and inflammatory markers in experimental testicular ischaemia/reperfusion injury in rats. *Andrologia* **2020**, *13714. [CrossRef] [PubMed*
Biomolecules 2020, 10, 1374

64. Sassi, A.; Boubaker, J.; Loussaief, A.; Jomaa, K.; Ghedira, K.; Chekir-Ghedira, L. Protective Effect of Chrysin, a Dietary Flavone against Genotoxic and Oxidative Damage Induced by Mitomycin C in Balb/C Mice. Nutr. Cancer 2020, 1–10. [CrossRef] [PubMed]

65. Yao, J.; Jiang, M.; Zhang, Y.; Liu, X.; Li, Y.; Feng, G. Chrysin alleviates allergic inflammation and airway remodeling in a murine model of chronic asthma. Int. Immunopharmacol. 2016, 32, 24–31. [CrossRef]

66. Lee, E.-J.; Kang, M.-K.; Kim, Y.-H.; Kim, D.Y.; Oh, H.; Kim, S-I.; Oh, S.Y.; Kang, Y.-H. Dietary Chrysin Suppresses Formation of Actin Cytoskeleton and Focal Adhesion in AGE-Exposed Mesangial Cells and Diabetic Kidney: Role of Autophagy. Nutrients 2019, 11, 127. [CrossRef]

67. Bortolotto, V.C.; Araujo, S.M.; Pinheiro, F.C.; Poetini, M.R.; De Paula, M.T.; Meichtry, L.B.; De Almeida, F.P.; Musachio, E.A.S.; Guerra, G.P.; Prigol, M. Modulation of glutamate levels and Na+, K+-ATPase activity contributes to the chrysin memory recovery in hypothyroidism mice. Physiol. Behav. 2020, 222, 112892. [CrossRef]

68. Song, Y.; Wu, W.; Sheng, L.; Jiang, B.; Li, X.; Cai, K. Chrysin ameliorates hepatic steatosis induced by a diet deficient in methionine and choline by inducing the secretion of hepatocyte nuclear factor 4α-dependent very low-density lipoprotein. J. Biochem. Mol. Toxicol. 2020, 34, e22497. [CrossRef]

69. Yang, M.; Xiong, J.; Zou, Q.; Wang, D.-D.; Huang, C. Chrysin attenuates interstitial fibrosis and improves cardiac function in a rat model of acute myocardial infarction. J. Mol. Histol. 2018, 49, 555–565. [CrossRef]

70. Choi, J.H.; Yun, J.W. Chrysin induces brown fat–like phenotype and enhances lipid metabolism in 3T3-L1 adipocytes. Nutrients 2016, 32, 1002–1010. [CrossRef]

71. Pai, S.A.; Munshi, R.P.; Panchal, F.H.; Gaur, I.-S.; Juvekar, A.R. Chrysin ameliorates nonalcoholic fatty liver disease in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 2019, 392, 1617–1628. [CrossRef] [PubMed]

72. Mohammadi, A.; Kazemi, S.; Hosseini, M.; Varzi, H.N.; Feyzi, F.; Morakabati, P.; Moghadamnia, A.A.; Mohammadi, A. Chrysin Effect in Prevention of Acetaminophen-Induced Hepatotoxicity in Rat. Chem. Res. Toxicol. 2019, 32, 2329–2337. [CrossRef] [PubMed]

73. Xu, M.; Shi, H.; Liu, D. Chrysin protects against renal ischemia reperfusion induced tubular cell apoptosis and inflammation in mice. Exp. Ther. Med. 2019, 17, 2256–2262. [CrossRef] [PubMed]

74. Melekoğlu, R.; Çifçi, O.; Eraslan, S.; Alan, S.; Başak, N. The Protective Effects of Glycyrrhetinic Acid and Chrysin against Ischemia-Reperfusion Injury in Rat Ovaries. BioMed Res. Int. 2018, 2018, 5421308. [CrossRef]

75. Yao, Y.; Chen, L.; Xiao, J.; Wang, C.; Jiang, W.; Zhang, R.; Hao, J. Chrysin Protects against Focal Cerebral Ischemia/Reperfusion Injury in Mice through Attenuation of Oxidative Stress and Inflammation. Int. J. Mol. Sci. 2014, 15, 20913–20926. [CrossRef]

76. Saliba-Gustafsson, P.; Pedrelli, M.; Gertow, K.; Werngren, O.; Janas, V.; Pourtemour, S.; Baldassarre, D.; Tremoli, E.; Veglia, F.; Rauramaa, E.; et al. Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy. J. Intern. Med. 2019, 286, 660–675. [CrossRef]

77. Krishnamoorthy, A.; Sevanan, M.; Mani, S.; Balu, M.; Balaji, S.; Ramajayan, P. Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson’s disease mouse model. Neurosci. Lett. 2019, 709, 134382. [CrossRef]

78. Rashno, M.; Ghaderi, S.; Nesari, A.; Khorsandi, L.; Farbood, Y.; Sarkaki, A. Chrysin attenuates traumatic brain injury-induced recognition memory decline, and anxiety/depression-like behaviors in rats: Insights into underlying mechanisms. Psychopharmacology 2020, 237, 1–13. [CrossRef]

79. Dong, F.; Zhang, J.; Zhu, S.; Lan, T.; Yang, J.; Li, L. Chrysin Alleviates Chronic Hypoxia–Induced Pulmonary Hypertension by Reducing Intracellular Calcium Concentration in Pulmonary Arterial Smooth Muscle Cells. J. Cardiovasc. Pharmacol. 2019, 74, 426–435. [CrossRef]

80. Li, H.-J.; Wu, N.-L.; Pu, C.-M.; Hsiao, C.-Y.; Chang, D.-C.; Hung, C.-F. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides. Sci. Rep. 2020, 10, 2932. [CrossRef]

81. Koc, F.; Tekeli, M.Y.; Karbur, M.; Karayigit, M.O.; Liman, B.C. The effects of chrysin on lipopolysaccharide-induced sepsis in rats. J. Food Biochem. 2020, e13359. [CrossRef] [PubMed]

82. Del Fabbro, L.; De Gomes, M.G.; Souza, L.C.; Goes, A.R.; Boeira, S.P.; Oliveira, M.S.; Furian, A.F.; Jesse, C.R. Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice. J. Neuroimmunol. 2019, 335, 577007. [CrossRef] [PubMed]
83. Wei, Y.; Zheng, Q.; Tang, G.; Song, C.; Wang, G.; Zhang, Y.; Xiao, Y.; Zeng, X.; Wang, Z.; Xiao, J.; et al. Synthesis and Anti-Thyroid Cancer Effect of Iodo-Chrysin Derivatives. Med. Chem. 2015, 12, 441–447. [CrossRef] [PubMed]

84. Sulaiman, G.M.; Jabir, M.S.; Hameed, A.H. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity. Artif. Cells Nanomed. Biotechnol. 2018, 46, 708–720. [CrossRef] [PubMed]

85. Andrade, N.; Andrade, S.; Silva, C.; Rodrigues, I.; Guardaço, L.; Guimarães, J.T.; Keating, E.; Martel, F. Chronic consumption of the dietary polyphenol chrysin attenuates metabolic disease in in fructose-fed rats. Eur. J. Nutr. 2019, 59, 151–165. [CrossRef] [PubMed]

86. Prajit, R.; Sritawan, N.; Suwannakot, K.; Naewla, S.; Aranarochana, A.; Sirichoat, A.; Pannangrong, W.; Wigmore, P.; Welbat, J.U. Chrysin Protects against Memory and Hippocampal Neurogenesis Depletion in D-Galactose-Induced Aging in Rats. Nutrients 2020, 12, 1100. [CrossRef]

87. Shooshtari, M.K.; Sarkaki, A.; Mansouri, S.M.T.; Badavi, M.; Khorsandi, L.; Dehcheshmeh, M.G.; Farbood, Y. Protective effects of Chrysin against memory impairment, cerebral hyperemia and oxidative stress after cerebral hypoperfusion and reperfusion in rats. Metab. Brain Dis. 2019, 35, 401–412. [CrossRef]

88. Khezri, S.; Sabzalipour, T.; Jahedsani, A.; Azizian, S.; Atashbar, S.; Salimi, A. Chrysin ameliorates aluminum phosphate-induced oxidative stress and mitochondrial damages in rat cardiomyocytes and isolated mitochondria. Environ. Toxicol. 2020. [CrossRef]

89. Baykalir, B.G.; Arslan, A.S.; Mutlu, S.I.; Ak, T.P.; Seven, I.; Seven, P.T.; Yaman, M.; Gul, H.F. The protective effect of chrysin against carbon tetrachloride-induced kidney and liver tissue damage in rats. Int. J. Vitam. Nutr. Res. 2020, 1–12. [CrossRef]

90. Temel, Y.; Kucuklier, S.; Yildirim, S.; Caglayan, C.; Kandemir, F.M. Protective effect of chrysin on cyclophosphamide-induced hepatotoxicity and nephrotoxicity via the inhibition of oxidative stress, inflammation, and apoptosis. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2019, 393, 325–337. [CrossRef]

91. Liao, Z.-Y.; Li, H.-J.; Wu, C.-C.; Lo, H.-M.; Chang, D.-C.; Hung, C.-F. Chrysin Inhibits High Glucose-Induced Migration on Chorioretinal Endothelial Cells via VEGF and VEGFR Down-Regulation. Int. J. Mol. Sci. 2020, 21, 5541. [CrossRef] [PubMed]

92. Wojnar, W.; Zych, M.; Borymski, S.; Kaczmarsczyk-Sedlak, I. Chrysin Reduces Oxidative Stress but Does Not Affect Polyol Pathway in the Lenses of Type 1 Diabetic Rats. Antioxidants 2020, 9, 160. [CrossRef] [PubMed]

93. Fagundes, F.L.; Pfifer, G.D.M.; Périco, L.L.; Rodrigues, V.P.; Lima, C.A.H.; Santos, R.D.C.D. Chrysin Modulates Genes Related to Inflammation, Tissue Remodeling, and Cell Proliferation in the Gastric Ulcer Healing. Int. J. Mol. Sci. 2020, 21, 760. [CrossRef] [PubMed]

94. DeSantis, C.E.; Bryant, L.; Jemal, A. Breast cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 438–451. [CrossRef] [PubMed]

95. Wang, C.; Kar, S.; Bai, X.; Cai, W.; Arfuso, F.; Sethi, G.; Lobie, P.E.; Goh, B.C.; Lim, L.H.K.; Hartman, M.; et al. Triple negative breast cancer in Asia: An insider’s view. Front. Pharmacol. 2020, 11, 573. [CrossRef]

96. Haque, M.; Desai, K.V. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front. Endocrinol. 2019, 10, 573. [CrossRef]

97. Pandey, K.; An, H.-J.; Kim, S.K.; Lee, S.A.; Kim, S.; Lim, S.M.; Kim, G.M.; Sohn, J.; Moon, Y.W. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int. J. Cancer 2019, 145, 1179–1188. [CrossRef]

98. Bhuvalanalakshmi, G.; Rangappa, K.S.; Dharmarajan, A.; Sethi, G.; Kumar, A.P.; Warrier, S. Basappr Breast Cancer Stem-Like Cells Are Inhibited by Diosgenin, a Steroidal Saponin, by the Attenuation of the Wnt β-Catenin Signaling via the Wnt Antagonist Secreted Frizzled Related Protein-4. Front. Pharmacol. 2017, 8, 124. [CrossRef]

99. Chen, L.; Yousef, E.; Samy, R.P.; Shanmugam, M.K.; et al. PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. Mol. Cancer Ther. 2017, 16, 2528–2542. [CrossRef]
101. Wang, L.; Wang, C.; Tao, Z.; Zhao, L.; Zhu, Z.; Wu, W.; He, Y.; Chen, H.; Zheng, B.; Huang, X.; et al. Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer. J. Exp. Clin. Cancer Res. 2019, 38, 460. [CrossRef] [PubMed]

102. Zhang, W.; Jiang, H.; Chen, Y.; Ren, F. Resveratrol chemosensitizes Adriamycin-resistant breast cancer cells by modulating miR-122-5p. J. Cell. Biochem. 2019, 120, 16283–16292. [CrossRef] [PubMed]

103. Shanmugam, M.K.; Ahn, K.S.; Hsu, A.; Woo, C.C.; Yuan, Y.; Tan, K.H.B.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A.; Koh, A.P.F.; et al. Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Binding Axis. Front. Pharmacol. 2018, 9, 1294. [CrossRef] [PubMed]

104. Liu, L.; Ahn, K.S.; Shanmugam, M.K.; Wang, H.; Shen, H.; Arfuso, F.; Chinnathambi, A.; Alharbi, S.A.; Chang, Y.; Sethi, G.; et al. Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. J. Cell. Biochem. 2018, 120, 4504–4513. [CrossRef]

105. Maasomi, Z.J.; Soltanahmadid, Y.P.; Dadashpour, M.; Alipour, S.; Abolhasani, S.; Zarghami, N. Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells. Asian Pac. J. Cancer Prev. 2017, 18, 1283–1287.

106. Kolibaba, K.S.; Druker, B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta (BBA) Bioenergy 1997, 1333, F217–F248. [CrossRef]

107. Lacouture, M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 2006, 6, 803–812. [CrossRef]

108. Choowongkomon, K.; Sawatdichaikul, O.; Songtawee, N.; Limtrakul, J. Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database. Molecules 2010, 15, 4041–4054. [CrossRef]

109. Debnath, S.; Kanakaraju, M.; Islam, M.; Yeeravalli, R.; Sen, D.; Das, A. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents. Comput. Biol. Chem. 2019, 83, 107156. [CrossRef]

110. Yun, C.W.; Lee, J.H.; Lee, S.H. Hypoxia-induced PGC-1α Regulates Mitochondrial Function and Tumorigenesis of Colorectal Cancer Cells. Anticancer Res. 2019, 39, 4865–4876. [CrossRef]

111. Ren, S.; Liu, J.; Feng, Y.; Li, Z.; He, L.; Li, L.; Cao, X.; Wang, Z.; Zhang, Y. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b in breast cancer under hypoxia. J. Exp. Clin. Cancer Res. 2019, 38, 388. [CrossRef] [PubMed]

112. Multhoff, G.; Vaupel, P. Hypoxia Compromises Anti-Cancer Immune Responses. Adv. Exp. Med. Biol. 2020, 131–143. [CrossRef]

113. Brizel, D.M.; Scully, S.P.; Harrelson, J.M.; Layfield, L.J.; Bean, J.M.; Prosnitz, L.R.; Dewhirst, M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56, 941–943. [PubMed]

114. Hockel, M.; Schlenker, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56, 4509–4515.

115. Minet, E.; Michel, G.; Mottet, D.; Raes, M.; Michiels, C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic. Biol. Med. 2001, 31, 847–855. [CrossRef]

116. Jung, J.E.; Lee, H.-G.; Cho, I.-H.; Chung, D.H.; Yoon, S.-H.; Yang, Y.M.; Lee, J.W.; Choi, S.; Park, J.-W.; Ye, S.-K.; et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005, 19, 1296–1298. [CrossRef]

117. Barr, M.P.; Bouchier-Hayes, D.J.; Harney, J.J. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int. J. Oncol. 2008, 32, 41–48. [CrossRef]

118. Zhang, J.; Lu, A.; Beech, D.; Jiang, B.; Lu, Y. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. Cancer Ther. 2007, 5, 273–286.

119. Lirdprapamongkol, K.; Sakurai, H.; Abdelhamed, S.; Yokoyama, S.; Maruyama, T.; Athikomkulchai, S.; Viriyaroj, A.; Awale, S.; Yagit, H.; Ruchirawat, S.; et al. A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells. Oncol. Rep. 2013, 30, 2357–2364. [CrossRef]

120. Park, J.; Kim, Y.; Park, E.H.; Lee, S.; Kim, H.; Kim, A.; Lee, S.B.; Shim, S.; Jang, H.; Myung, J.K.; et al. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. Cancer Sci. 2019, 110, 2834–2845. [CrossRef]

121. Xue, J.; Li, L.; Li, N.; Li, F.; Qin, X.; Li, T.; Liu, M. Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. Eur. J. Pharmacol. 2019, 859, 172541. [CrossRef] [PubMed]
122. Rasouli, S.; Zarghami, N. Synergistic Growth Inhibitory Effects of Chrysirin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression. *Asian Pac. J. Cancer Prev.* 2018, 19, 977–982. [PubMed]

123. International Agency for Research on Cancer. *Chromium, Nickel and Welding. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; IARC: Lyon, France, 1990; Volume 49.*

124. Jung, Y.Y.; Shanmugam, M.K.; Narula, A.S.; Kim, C.; Lee, J.H.; Namjoshi, O.A.; Blough, B.E.; Sethi, G.; Ahn, K.S. Oxymatrine Attenuates Tumor Growth and Deactivates STAT3 Signaling in a Lung Cancer Xenograft Model. *Cancers* 2019, 11, 49. [CrossRef] [PubMed]

125. Lee, J.H.; Kim, C.; Lee, S.-G.; Yang, W.M.; Um, J.-Y.; Sethi, G.; Ahn, K.S. Ophiopogonin D modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells. *Phytotherapy Research* 2018, 40, 165–175. [CrossRef]

126. Kuo, C.-Y.; Wong, R.-H.; Lin, J.-Y.; Lai, J.-C.; Lee, H. Accumulation of Chromium and Nickel Metals in Lung Tumors from Lung Cancer Patients in Taiwan. *J. Toxicol. Environ. Health Part A* 2006, 69, 1337–1344. [CrossRef]

127. Huang, H.-H.; Huang, J.-Y.; Lung, C.-C.; Wu, C.-L.; Ho, C.-C.; Sun, Y.-H.; Ko, P.-C.; Su, S.-Y.; Chen, S.-C.; Wang, B.-Y. Cell-type specificity of lung cancer associated with low-dose soil heavy metal contamination in Taiwan: An ecological study. *BMC Public Health* 2013, 13, 330. [CrossRef]

128. Wu, C.-H.; Tang, S.C.; Wang, P.-H.; Lee, H.; Ko, J.-I. Nickel-induced Epithelial-Mesenchymal Transition by Reactive Oxygen Species Generation and E-cadherin Promoter Hypermethylation. *J. Biol. Chem.* 2012, 287, 25292–25302. [CrossRef]

129. Chiou, Y.-H.; Liou, S.-H.; Wong, R.-H.; Chen, C.-Y.; Lee, H. Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. *Toxicol. Lett.* 2015, 237, 46–54. [CrossRef]

130. Guo, H.; Deng, H.; Cui, H.; Peng, X.; Fang, J.; Zuo, Z.; Deng, J.; Wang, X.; Wu, B.; Chen, K. Nickel chloride (NiCl2)-caused inflammatory responses via activation of NF-κB pathway and reduction of anti-inflammatory mediator expression in the kidney. *Oncotarget* 2015, 6, 28607–28620. [CrossRef]

131. Basith, S.; Manavalan, B.; Yoo, T.H.; Kim, S.G.; Choi, S. Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense. *Arch. Pharmacal. Res.* 2012, 35, 1297–1316. [CrossRef]

132. Yesudhas, D.; Gosu, V.; Anwar, M.A.; Choi, S. Multiple Roles of Toll-Like Receptor 4 in Colorectal Cancer. *Front. Immunol.* 2014, 5, 334. [CrossRef] [PubMed]

133. Puar, Y.R.; Shanmugam, M.K.; Fan, L.; Arfuso, F.; Sethi, G.; Tergaonkar, V. Evidence for the Involvement of the Master Transcription Factor NF-kB in Cancer Initiation and Progression. *Biomedicines* 2018, 6, 82. [CrossRef] [PubMed]

134. Wu, T.C.; Chan, S.T.; Chang, C.N.; Yu, P.S.; Chuang, C.H.; Yeh, S.L. Quercetin and chrysin inhibit nickel-induced invasion and migration by downregulation of TLR4/NF-κB signaling in A549 cells. *Chem. Biol. Interact.* 2018, 292, 101–109. [CrossRef] [PubMed]

135. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. *CA Cancer J. Clin.* 2016, 66, 7–30. [CrossRef]

136. Lee, J.H.; Kim, C.; Baek, S.H.; Ko, J.-H.; Lee, S.G.; Yang, W.M.; Um, J.-Y.; Sethi, G.; Ahn, K.S. Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer. *Oncotarget* 2016, 8, 17700–17711. [CrossRef]

137. Zhang, J.; Ahn, K.S.; Kim, C.; Shanmugam, M.K.; Siveen, K.S.; Arfuso, F.; Samym, R.P.; Devasagayam, A.; Lim, L.H.K.; Wang, L.; et al. Nimboide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model. *Antioxid. Redox Signal.* 2016, 24, 575–589. [CrossRef]

138. Mandal, D.; Rossi, R.E.; Pericleous, M.; Whyand, T.; Caplin, M. Prostate cancer and the influence of dietary factors and supplements: A systematic review. *Nutr. Metab.* 2014, 11, 30. [CrossRef]

139. Potosky, A.L.; Haque, R.; Cassidy-Bushrow, A.E.; Vood, M.U.; Jiang, M.; Tsai, H.-T.; Luta, G.; Keating, N.L.; Smith, M.R.; Eeden, S.K.V.D. Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer. *J. Clin. Oncol.* 2014, 32, 1324–1330. [CrossRef]

140. Du, F.; Sun, L.; Chu, Y.; Li, T.; Lei, C.; Wang, X.; Jiang, M.; Min, Y.; Lu, Y.; Zhao, X.; et al. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. *Cancer Commun.* 2018, 38, 45. [CrossRef]
141. Presti, D.; Quaquarini, E. The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments. *Cancers* 2019, *11*, 1242. [CrossRef]

142. Dai, X.; Wang, L.; Devisagammi, A.; Looi, C.Y.; Karthikeyan, C.; Trivedi, P.; Chinnathambi, A.; Alharbi, S.A.; Arfuso, F.; Dharmaraj, A.; et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. *Oncotarget* 2017, *8*, 12831–12842. [CrossRef] [PubMed]

143. Ong, P.S.; Wang, L.Z.; Dai, X.; Tseng, S.H.; Loo, S.J.; Sethi, G. Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. *Front. Pharmacol.* 2016, *7*, 395. [CrossRef] [PubMed]

144. Ryu, S.; Lim, W.; Bazer, F.W.; Song, G. Chrysins induce death of prostate cancer cells by inducing ROS and ER stress. *J. Cell. Physiol.* 2017, *232*, 3786–3797. [CrossRef] [PubMed]

145. Laudisi, F.; Di Grazia, A.; De Simone, V.; Cherubini, F.; Colantonio, A.; Ortenzi, A.; Franzè, E.; Di Nallo, V.; Di Fusco, D.; Monteleone, I.; et al. Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helminthic drug rafoxanide. *Cancer Lett.* 2019, *462*, 1–11. [CrossRef]

146. Okubo, K.; Iso, M.; Asano, T.; Sato, A. Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells. *Anticancer Res.* 2019, *39*, 5891–5901. [CrossRef]

147. Li, X.; Zeng, Z.; Wang, J.; Wu, Y.; Chen, W.; Zheng, L.; Xi, T.; Wang, A.; Lu, Y. MicroRNA-9 and breast cancer. *Nano Scale Res. Lett.* 2020, *15*, 73. [CrossRef]

148. Niyonizigiye, I.; Ngabire, D.; Patil, M.P.; Singh, A.A.; Kim, G.-D. In vitro induction of endoplasmic reticulum stress in human cervical adenocarcinoma HeLa cells by fucoidan. *Int. J. Biol. Macromol.* 2019, *137*, 844–852. [CrossRef]

149. Jessmon, P.; Boulanger, T.; Zhou, W.; Patwardhan, P. Epidemiology and treatment patterns of epithelial ovarian cancer. *Expert Rev. Anticancer. Ther.* 2017, *17*, 427–437. [CrossRef]

150. Guo, X.; Mei, J.; Jing, Y.; Wang, S. Curcumin-Loaded Nanoparticles with Low-Intensity Focused Ultrasound-Induced Phase Transformation as Tumor-Targeted and pH-Sensitive Theranostic Nanoplatform of Ovarian Cancer. *Biomed. Pharmacother.* 2019, *122*, 109687. [CrossRef]

151. Zhang, Y.; Yang, S.; Yang, Y.; Liu, T. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. *Infect. Agents Cancer* 2019, *14*, 27–29. [CrossRef]

152. Bock, F.J.; Tait, S.W.G. Mitochondria as multifaceted regulators of cell death. *Nat. Rev. Mol. Cell Biol.* 2019, *21*, 85–100. [CrossRef] [PubMed]

153. Lim, W.; Ryu, S.; Bazer, F.W.; Kim, S.-M.; Song, G. Chrysins attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction. *J. Cell. Physiol.* 2017, *233*, 3129–3140. [CrossRef] [PubMed]

154. Tewari, D.; Patni, P.; Bishayee, A.; Sah, A.N.; Bishayee, A. Natural products targeting the PI3K-AKT-mTOR and CDK4/6 Pathways in endometrial cancer: A novel therapeutic strategy. *Semin. Cancer Biol.* 2019, *36*, 5891–5901. [CrossRef]

155. Shi, N.; Yu, H.; Chen, T. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway. *OncoTargets Ther.* 2019, *12*, 7637–7647. [CrossRef]

156. Jiang, C.; Ma, Z.; Zhang, G.; Yang, X.; Du, Q.; Wang, W. CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway. *Cancer Manag. Res.* 2019, *11*, 10135–10143. [CrossRef] [PubMed]

157. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2019: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018, *68*, 394–424. [CrossRef] [PubMed]

158. Manu, K.A.; Shanmugam, M.K.; Ramachandran, L.; Li, F.; Siveen, K.S.; Chinnathambi, A.; Zayed, M.; Alharbi, S.A.; Arfuso, F.; Kumar, A.P.; et al. Isorhamnetin augments the anti-tumor effects of capecitabine in preclinical models of HR-positive breast cancer. *Cancers* 2019, *11*, 1242. [CrossRef]

159. Hwang, S.T.; Kim, C.; Lee, J.H.; Chinnathambi, A.; Alharbi, S.A.; Shair, O.H.; Sethi, G.; Ahn, K.S. Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. *Phytother. Res.* 2019, *33*, 152907. [CrossRef]

160. Manu, K.A.; Shanmugam, M.K.; Li, F.; Chen, L.; Siveen, K.S.; Ahn, K.S.; Kumar, A.P.; Sethi, G. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. *J. Mol. Med.* 2013, *91*, 267–276. [CrossRef]
161. He, Y.-F.; Li, B.-Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA. *Science* 2011, 333, 1303–1307. [CrossRef] [PubMed]

162. Yatagai, N.; Saito, T.; Akazawa, Y.; Hayashi, T.; Yanai, Y.; Tsuyama, S.; Ueyama, H.; Murakami, T.; Watanabe, S.; Nagahara, A.; et al. TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. *Virchows Arch.* 2018, 474, 315–324. [CrossRef] [PubMed]

163. Liu, H.; Wang, H.; Li, C.; Zhang, T.; Meng, X.; Zhang, Y.; Qian, H. Spheres from cervical cancer cells display stemness and cancer drug resistance. *Cell Death Discov.* 2019, 5, 100103. [CrossRef] [PubMed]

164. Xu, C.; Li, B.; Zhao, S.; Jin, B.; Jia, R.; Ge, J.; Xu, H. MicroRNA-186-5p Inhibits Proliferation And Metastasis Of Esophageal Cancer By Mediating HOXA9. *OncoTargets Ther.* 2019, 12, 8905–8914. [CrossRef] [PubMed]

165. Mohammadian, F.; Soltanahmadid, Y.P.; Zarghami, F.; Akbarzadeh, A.; Zarghami, N. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. *Artif. Cells Nanomed. Biotechnol.* 2016, 45, 1201–1206. [CrossRef] [PubMed]

166. Liu, H.; Wang, H.; Li, C.; Zhang, T.; Meng, X.; Zhang, Y.; Qian, H. Spheres from cervical cancer cells display stemness and cancer drug resistance. *Oncol. Lett.* 2016, 12, 2184–2188. [CrossRef] [PubMed]

167. Cheng, Y.-M.; Shen, C.-J.; Chang, C.-C.; Chou, C.-Y.; Tsai, C.-C.; Hsu, Y.-C. Inducement of apoptosis by cucurbitacin E, a tetracyclic triterpenes, through death receptor 5 in human cervical cancer cell lines. *Cell Death Discov.* 2017, 3, 17014. [CrossRef] [PubMed]

168. Ningegowda, R.; Shivananju, N.S.; Rajendran, P.; Rangappa, K.S.; Chinnathambi, A.; Li, F.; Achar, R.R.; Shanmugam, M.K.; Bist, P.; Alharbi, S.A.; et al. A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFα by abrogating NF-κB activation cascade. *Apoptosis* 2016, 22, 145–157. [CrossRef] [PubMed]

169. Rashid, S.; Labani, S.; Das, B.C. Knowledge, Awareness and Attitude on HPV, HPV Vaccine and Cervical Cancer among the College Students in India. *PLoS ONE* 2016, 11, e0166713. [CrossRef] [PubMed]

170. Ortiz-Sánchez, E.; Santiago-López, L.; Cruz-Domínguez, V.B.; Toledo-Guzmán, M.E.; Hernández-Cueto, D.; Muñiz-Hernández, S.; Garrido, E.; De León, D.C.; García-Carrancá, A. Characterization of cervical cancer stem cell-like cells: Phenotyping, stemness, and human papilloma virus co-receptor expression. *OncoTarget* 2016, 7, 31943–31954. [CrossRef] [PubMed]
179. Hazelbag, S.; Fleuren, G.J.; Baelen, H.J.; Schuuring, E.; Kenter, G.G.; Gorter, A. Cytokine Profile of Cervical Cancer Cells. *Gynecol. Oncol.* 2001, 83, 235–243. [CrossRef]
180. Wang, Q.; Zhang, C.; Walayat, S.; Chen, H.W.; Wang, Y. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2011, 158, 330–333. [CrossRef]
181. Yang, B.; Lu, Y.; Zhang, A.; Zhou, A.; Zhang, L.; Zhang, L.; Gao, L.; Zang, Y.; Tang, X.; Sun, L. Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells. *PLoS ONE* 2015, 10, e0129138.
182. Dong, W.; Chen, A.; Chao, X.; Li, X.; Cui, Y.; Xu, C.; Cao, J.; Ning, Y.; Cao, X. Chrysin Inhibits Proinflammatory Factor-Induced EMT Phenotype and Cancer Stem Cell-Like Features in HeLa Cells by Blocking the NF-κB/Twist Axis. *Cell. Physiol. Biochem.* 2019, 52, 1236–1250. [CrossRef] [PubMed]
183. Sinha, S.; Pokhrel, S.; Vaidya, B.N.; Joshee, N. In vitro micropropagation and callus induction in Scutellaria discolor colebr.–A medicinally important plant of Nepal. *Indian J. Plant Genet. Resour.* 1998, 12, 219–223.
184. Laishram, S.; Moirangthem, D.S.; Borah, J.C.; Pal, B.C.; Suman, P.; Gupta, S.K.; Kalita, M.C.; Talukdar, N.C. Chrysirich Scutellaria discolor Colebr. induces cervical cancer cell death via the induction of cell cycle arrest and caspase-dependent apoptosis. *Life Sci.* 2015, 143, 105–113. [CrossRef] [PubMed]
185. Samec, M.; Lišková, A.; Koklesová, L.; Samuel, S.M.; Zhai, K.; Buhrmann, C.; Varghese, E.; Abotaleb, M.; Qaradakhi, T.; Zulli, A.; et al. Flavonoids against the Warburg phenotype—Concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. *EPMA J.* 2020, 11, 377–398. [CrossRef]
186. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. *Cell* 2011, 144, 646–674. [CrossRef]
187. Heiden, M.G.V.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* 2009, 324, 1029–1033. [CrossRef]
188. Mathupala, S.P.; Ko, Y.H.; Pedersen, P.L. Hexokinase-2 bound to mitochondria: Cancer’s stygian link to the “Warburg effect” and a pivotal target for effective therapy. *Semin. Cancer Biol.* 2009, 19, 17–24. [CrossRef] [PubMed]
189. Yoshida, G.J. Metabolic reprogramming: The emerging concept and associated therapeutic strategies. *J. Exp. Clin. Cancer Res.* 2015, 34, 1–10. [CrossRef] [PubMed]
190. Rho, M.; Kim, J.; Lee, C.D.; Lee, Y.M.; Lee, H.E.; Kim, M.A.; Lee, H.S.; Kim, W.H. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. *Anticancer Res.* 2007, 27, 251–258.
191. Suh, D.H.; Kim, M.A.; Kim, H.; Kim, M.K.; Kim, H.-S.; Chung, H.H.; Kim, Y.B.; Song, Y.S. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. *Clin. Exp. Med.* 2013, 14, 345–353. [CrossRef]
192. Palmieri, D.; Fitzgerald, D.; Shreeve, S.M.; Hua, E.; Brondier, J.L.; Weil, R.J.; Davis, S.; Stark, A.M.; Merino, M.J.; Kurek, R.; et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. *Mol. Cancer Res.* 2009, 7, 1438–1445. [CrossRef] [PubMed]
193. Guo-Qing, P.; Yuan, Y.; Cai-Gao, Z.; Hongling, Y.; Gonghua, H.; Yan, T. A study of association between expression of hOGG1, VDAC1, HK-2 and cervical carcinoma. *J. Exp. Clin. Cancer Res.* 2010, 29, 129. [CrossRef] [PubMed]
194. Xu, D.; Jin, J.; Yu, H.; Zhao, Z.; Ma, D.; Zhang, C.; Jiang, H. Chrysirin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. *J. Exp. Clin. Cancer Res.* 2017, 36, 44. [CrossRef] [PubMed]
195. Seydi, E.; Rahimpour, Z.; Salimi, A.; Pourahmad, J. Selective toxicity of chrysirin on mitochondria isolated from liver of a HCC rat model. *Bioorg. Med. Chem.* 2019, 27, 115163. [CrossRef] [PubMed]
196. Lee, C.; Cheung, S.T. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. *Cancers* 2019, 11, 1646. [CrossRef] [PubMed]
197. Swamy, S.G.; Kameshwar, V.H.; Shubha, P.B.; Looi, C.Y.; Shanmugam, M.K.; Arfuso, F.; Dharmarajan, A.; Sethi, G.; Swamy, S.N.; Bishayee, A. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. *Target. Oncol.* 2016, 12, 1–10. [CrossRef]
198. Dai, X.; Ahn, K.S.; Kim, C.; Siveen, K.S.; Ong, T.H.; Shanmugam, M.K.; Li, F.; Shi, J.; Kumar, A.P.; Wang, L.Z.; et al. Ascoschlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. *Mol. Oncol.* 2015, 9, 818–833. [CrossRef]
Biomolecules 2020, 10, 1374

199. Dai, X.; Ahn, K.S.; Wang, L.Z.; Kim, C.; Deivasigammi, A.; Arfuso, F.; Um, J.-Y.; Kumar, A.P.; Chang, Y.-C.; Kumar, D.; et al. Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. *Mol. Cancer Ther.* **2016**, *15*, 2966–2976. [CrossRef]

200. Jiang, J.; Chen, Y.; Dong, T.; Yue, M.; Zhang, Y.; An, T.; Zhang, J.; Liu, P.; Yang, X. Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway. *Oncol. Lett.* **2019**, *17*, 4505–4513. [CrossRef]

201. Mohan, C.D.; Bharathkumar, H.; Bulusu, K.C.; Pandey, V.; Rangappa, S.; Fuchs, J.E.; Shamugam, M.K.; Dai, X.; Li, F.; Deivasigamani, A.; et al. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. *J. Biol. Chem.* **2014**, *289*, 34296–34307. [CrossRef]

202. Mastron, J.K.; Siveen, K.S.; Sethi, G.; Bishayee, A. Silymarin and hepatocellular carcinoma. *Anti-Cancer Drugs* **2015**, *26*, 475–486. [CrossRef] [PubMed]

203. Zhang, Y.; Chen, F.; Xiao, X.; Pan, W.; Yuan, Q.; Cao, J. Chrysin inhibits sphere formation in SMMC-7721 cells via modulation of SHP-1

204. Kuphal, S.; Bosserhoff, A.-K. Recent progress in understanding the pathology of malignant melanoma. *J. Pathol.* **2009**, *219*, 400–409. [CrossRef] [PubMed]

205. Morton, D.; Eibber, F.R.; Malmgren, R.A.; Wood, W.C. Immunological factors which influence response to immunotherapy in malignant melanoma. *Surgery* **1970**, *68*, 158.

206. Bittner, M.; Meltzer, P.; Chen, Y.; Jiang, Y.; Seftor, E.; Hendrix, M.; Radmacher, M.; Simon, R.; Yakhini, Z.; Ben-Dor, A.; et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature* **2000**, *406*, 536–540. [CrossRef]

207. Álvarez-Garcia, V.; Tawil, Y.; Wise, H.M.; Leslie, N.R. Mechanisms of PTEN loss in cancer: It’s all about diversity. *Semin. Cancer Biol.* **2019**, *59*, 66–79. [CrossRef]

208. Ghazaeian, M.; Khorsandi, K.; Hosseinzadeh, R.; Naderi, A.; Abrahamse, H. Curcumin–silica nanocomplex preparation, hemoglobin and DNA interaction and photocytotoxicity against melanoma cancer cells. *J. Biomed. Struct. Dyn.* **2020**, *1–11*. [CrossRef]

209. Yang, H.-Z.; Zhang, J.; Zeng, J.; Liu, S.; Zhou, F.; Zhang, F.; Giampieri, F.; Cianciosi, D.; Forbes-Hernandez, T.Y.; Ansary, J.; et al. Resveratrol inhibits the proliferation of melanoma cells by modulating cell cycle. *Int. J. Food Sci. Nutr.* **2019**, *71*, 84–93. [CrossRef]

210. Chen, Y.; Li, H.; Zhang, G.-X.; Wu, Y.; Xiao, J.; Liu, J.; Qiu, P.; Liu, X.; Sun, L.; Du, B.; et al. Synergistic inhibitory effect of resveratrol and TK/GCV therapy on melanoma cells. *J. Cancer Res. Clin. Oncol.* **2020**, *146*, 1489–1499. [CrossRef]

211. Sassi, A.; Maatouk, M.; El Gueder, D.; Bézouich, I.M.; Hatira, S.A.-B.; Jemni-Yacoub, S.; Ghedira, K.; Chekir, L. Chrysins, a natural and biologically active flavonoid suppresses tumor growth of mouse B16F10 melanoma cells: In vitro and In vivo study. *Chem. Interact.* **2018**, *283*, 10–19. [CrossRef]

212. Folgueras, A.R.; Pendas, A.M.; Sánchez, L.M.; López-Otín, C. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. *Int. J. Dev. Biol.* **2004**, *48*, 411–424. [PubMed]

213. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. *Cell 2010*, **141**, 52–67. [CrossRef] [PubMed]

214. Babykutty, S.; Suboj, P.; Srinivas, P.; Nair, A.S.; Chandramohan, K.; Gopala, S. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. *Clin. Exp. Metastasis* **2012**, *29*, 471–492. [CrossRef] [PubMed]

215. Dung, T.D.; Feng, C.C.; Kuo, W.W.; Piao, P.; Chung, L.C.; Chang, S.H.; Hsu, H.H.; Tsai, F.J.; Lin, Y.M.; Huang, C.Y. Suppression of plasminogen activators and the MMP-2/9 pathway by a Zanthoxylum avicennae extract to inhibit the HA22T human hepatocellular carcinoma cell migration and invasion effects in vitro and in vivo via phosphatase 2A activation. *Biosci. Biotechnol. Biochem.* **2013**, *77*, 1814–1821. [CrossRef]

216. Cai, Z.; Zhang, F.; Chen, W.; Zhang, J.; Li, H. miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer. *OncoTargets Ther.* **2019**, *12*, 11805–11816. [CrossRef]

217. Xu, R.; Li, H.; Wu, S.; Qu, J.; Yuan, H.; Zhou, Y.; Lu, Q. MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53. *Int. Urol. Nephrol.* **2019**, *51*, 1771–1779. [CrossRef]
218. Almeida, T.C.; Guerra, C.C.C.; De Assis, B.L.G.; Soares, R.D.O.A.; Garcia, C.C.M.; Lima, A.A.; Da Silva, G.N. Antiproliferative and toxicogenic effects of resveratrol in bladder cancer cells with different TP53 status. *Environ. Mol. Mutagen.* 2019, 60, 740–751. [CrossRef]

219. Sun, N.; Liang, Y.; Chen, Y.; Wang, L.; Li, D.; Liang, Z.; Sun, L.; Wang, Y.; Niu, H. Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. *Int. J. Mol. Med.* 2019, 44, 2189–2200. [CrossRef]

220. Korac-Prlic, J.; Degoricija, M.; Vilović, K.; Haupt, B.; Ivanišević, T.; Franković, L.; Grivennikov, S.; Terzić, J. Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model. *Cancer Lett.* 2020, 490, 89–99. [CrossRef]

221. Sun, N.; Liang, Y.; Chen, Y.; Wang, L.; Li, D.; Liang, Z.; Sun, L.; Wang, Y.; Niu, H. Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. *Int. J. Mol. Med.* 2019, 44, 2189–2200. [CrossRef]

222. Xu, Y.; Tong, Y.; Ying, J.; Lei, Z.; Wan, L.; Zhu, X.; Ye, F.; Mao, P.; Wu, X.; Pan, R.; et al. Chrysín induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells. *OncoL. Lett.* 2018, 15, 9117–9125. [CrossRef] [PubMed]

223. Puccini, A.; Berger, M.D.; Naseem, M.; Tokunaga, R.; Battaglin, F.; Cao, S.; Hanna, D.L.; McSkane, M.; Soni, S.; Zhang, W.; et al. Colorectal cancer: Epigenetic alterations and their clinical implications. *Biochim. Biophys. Acta (BBA) Bioenergy* 2017, 1868, 439–448. [CrossRef] [PubMed]

224. Coppedè, F.; Lopomo, A.; Spisni, R.; Migliore, L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. *World J. Gastroenterol.* 2014, 20, 943–956. [CrossRef] [PubMed]

225. Lee, C.S.; Ryan, E.J.; Doherty, G.A. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation. *World J. Gastroenterol.* 2014, 20, 3751–3761. [CrossRef]

226. Crea, F.; Nobili, S.; Paolicchi, E.; Perrone, G.; Napoli, C.; Landini, I.; Danesi, R.; Mini, E. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. *Drug Resist. Updat.* 2011, 14, 280–296. [CrossRef]

227. Lin, Y.-M.; Chen, C.-I.; Hsiang, Y.-P.; Hsu, Y.-C.; Cheng, K.-C.; Chien, P.-H.; Pan, H.-L.; Lu, C.-C.; Chen, Y.-J. Chrysín Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. *Int. J. Mol. Sci.* 2018, 19, 1763. [CrossRef]

228. Eghtedardoost, M.; Ghazanfari, T.; Sadeghipour, A.; Hassan, Z.M.; Ghanei, M.; Ghavami, S. Delayed effects of sulfur mustard on autophagy suppression in chemically-injured lung tissue. *Int. Immunopharmacol.* 2020, 80, 105896. [CrossRef]

229. Patra, S.; Bhutia, S.K. Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives. *Semin. Cancer Biol.* 2020. [CrossRef]

230. Linder, B.; Kögel, D. Autophagy in Cancer Cell Death. *Biology* 2019, 8, 82. [CrossRef]

231. Teng, J.-F.; Qin, D.-L.; Mei, Q.-B.; Qu, W.-Q.; Pan, R.; Xiong, R.; Zhao, Y.; Law, B.Y.-K.; Wong, V.K.-W.; Tang, Y.; et al. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer. *Pharmacol. Res.* 2019, 147, 104396. [CrossRef] [PubMed]

232. Majeed, T.; Wani, I.A.; Hamdani, A.M.; Bhat, N.A. Effect of sonication and γ-irradiation on the physicochemical changes in pineapple fruit cv. Pattavia during stimulated sea shipment. *Food Sci. Nutr.* 2017, 5, 997–1003. [CrossRef] [PubMed]

233. Kang, J.A.; Song, H.-Y.; Byun, E.-H.; Ahn, N.-G.; Kim, H.-M.; Nam, Y.R.; Lee, G.H.; Jang, B.-S.; Choi, D.S.; Lee, D.-E.; et al. Gamma-irradiated black ginseng extract inhibits mast cell degranulation and suppresses atopic dermatitis-like skin lesions in mice. *Food Chem. Toxicol.* 2018, 111, 133–143. [CrossRef] [PubMed]

234. Song, H.-Y.; Kim, H.-M.; Mushtaq, S.; Kim, W.S.; Kim, Y.J.; Lim, S.-T.; Byun, E.-B. Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway. *J. Med. Food* 2019, 22, 713–721. [CrossRef] [PubMed]
236. Chinetti-Gbaguidi, G.; Fruchart, J.-C.; Staels, B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. *Inflamm. Res.* **2000**, *49*, 497–505. [CrossRef] [PubMed]

237. Weiskirchen, S.; Weiskirchen, R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? *Adv. Nutr.* **2016**, *7*, 706–718. [CrossRef]

238. Sikka, S.; Chen, L.; Sethi, G.; Kumar, A.P. Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer. *PPAR Res.* **2012**, *2012*, 1–14. [CrossRef]

239. Ramachandran, L.; Manu, K.A.; Shanmugam, M.K.; Li, F.; Siveen, K.S.; Vali, S.; Kapoor, S.; Abbasi, T.; Surana, R.; Smoot, D.T.; et al. Isorhamnetin Inhibits Proliferation and Invasion and Induces Apoptosis through the Modulation of Peroxisome Proliferator-activated Receptor γ Activation Pathway in Gastric Cancer. *J. Biol. Chem.* **2012**, *287*, 38028–38040. [CrossRef]

240. Berthold, D.R.; Pond, G.R.; Roessner, M.; De Wit, R.; Eisenberger, M.; Tannock, A.I.F. Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study. *Clin. Cancer Res.* **2008**, *14*, 2763–2767. [CrossRef]

241. Grau, R.; Punzón, C.; Fresno, M.; Íñiguez, M.A. Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. *Biochem. J.* **2006**, *395*, 81–88. [CrossRef]

242. Waxman, D.J. P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR. *Arch. Biochem. Biophys.* **1999**, *369*, 11–23. [CrossRef] [PubMed]

243. Danielson, Pá. The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans. *Curr. Drug Metab.* **2002**, *3*, 561–597. [CrossRef] [PubMed]

244. Thomas, M.; Winter, S.; Klumpp, B.; Turpeinen, M.; Klein, K.; Schwab, M.; Zanger, U.M. Peroxisome proliferator-activated receptor α agonists directly regulates transcription of cytochrome P450 CYP2C8. *Front. Pharmacol.* **2015**, *6*, 261. [CrossRef]

245. Khor, C.Y.; Khoo, B.Y. PPARα plays an important role in the migration activity, and the expression of CYP2S1 and CYP1B1 in chrysin-treated HCT116 cells. *Biotechnol. Lett.* **2020**, *42*, 1–15. [CrossRef] [PubMed]

246. Tang, Q.; Ji, F.; Guo, J.; Wang, J.; Li, Y.; Bao, Y. Directional modification of chrysin for exerting apoptosis and enhancing significantly anti-cancer effects of 10-hydroxy camptothecin. *Biomed. Pharmacother.* **2016**, *82*, 693–703. [CrossRef] [PubMed]

247. Li, H.Z.; Chen, Y.H.; Fang, Y.L.; Zhong, L.Y.; Yuan, Q.Q.; Xu, X.Y.; Cao, J.G. Effects of chrysin on sphere formation and CK2α expression of ovarian cancer stem-like cells derived from SKOV3 cell line. *Zhonghua Yi Xue Za Zhi* **2016**, *96*, 2013–2016. [PubMed]

248. Samarghandian, S.; Ashhari, J.T.; Davoodi, S. Chrysin reduces proliferation and induces apoptosis in the human prostate cancer cell line pc-3. *Clinics* **2011**, *66*, 1073–1079. [CrossRef]

249. Al-Oudat, B.A.; Alqudah, M.A.; Audat, S.A.; Al-Balas, Q.A.; El-Elimat, T.; Hassan, M.A.; Frhat, I.N.; Azaizeh, M.M. Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents and caspase-3/7 activators. *Drug Des. Devel. Ther.* **2019**, *13*, 423–433. [CrossRef]

250. Xie, Y.; Peng, X. Effects of chrysin on the apoptosis in oral squamous carcinoma KB cell line and the underlying mechanisms. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* **2012**, *38*, 340–344. [CrossRef] [PubMed]

251. Ni, Z.; He, J.; Wu, Y.; Hu, C.; Dai, X.; Yan, X.; Li, B.; Li, X.; Xiong, H.; Li, Y.; et al. AKT-mediated phosphorylation of ATG4B impairs mitochondrial activity and enhances the Warburg effect in hepatocellular carcinoma cells. *Autophagy* **2018**, *14*, 685–701. [CrossRef]

252. Hasanzadeh, M.; Samarghandian, S.; Azimi-Nezhad, M.; Borji, A.; Jabbari, F.; Forkhondeh, T.; Samini, M. Inhibitory and cytotoxic activities of chrysin on human breast adenocarcinoma cells by induction of apoptosis. *Pharmacogn. Mag.* **2016**, *12*, 436–540. [CrossRef] [PubMed]

253. Ren, S.-Z.; Wang, Z.-C.; Zhu, X.-H.; Zhu, D.; Li, Z.; Shen, F.-Q.; Duan, Y.-T.; Cao, H.; Zhao, J.; Zhu, H.-L. Design and biological evaluation of novel hybrids of 1,5-diarylpyrazole and Chrysin for selective COX-2 inhibition. *Bioorg. Med. Chem.* **2018**, *26*, 4264–4275. [CrossRef] [PubMed]

254. Yu, X.-M.; Phan, T.; Patel, P.N.; Jaskula-Sztul, R.; Chen, H.; Bs, P.N.P. Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. *Cancer* **2012**, *119*, 774–781. [CrossRef]
255. Nagasaka, M.; Hashimoto, R.; Inoue, Y.; Ishiuchi, K.; Matsuno, M.; Itoh, Y.; Tokugawa, M.; Ohoka, N.; Morishita, D.; Mizukami, H.; et al. Anti-Tumorigenic Activity of Chrysin from Oroxylum indicum via Non-Genotoxic p53 Activation through the ATM-Chk2 Pathway. *Molecules* **2018**, *23*, 1394. [CrossRef] [PubMed]

256. Celinska-Janowicz, K.; Zareba, I.; Lazarek, U.; Teul, J.; Tomczyk, M.; Palka, J.; Miltyk, W. Constituents of Propolis: Chrysin, Caffeic Acid, p-Coumaric Acid, and Ferulic Acid Induce PRODH/POX-Dependent Apoptosis in Human Tongue Squamous Cell Carcinoma Cell (CAL-27). *Front. Pharmacol.* **2018**, *9*, 336. [CrossRef] [PubMed]

257. Park, W.; Park, S.; Lim, W.; Song, G. Chrysin disrupts intracellular homeostasis through mitochondria-mediated cell death in human choriocarcinoma cells. *Biochem. Biophys. Res. Commun.* **2018**, *503*, 3155–3161. [CrossRef] [PubMed]

258. Bahadori, M.; Baharara, J.; Amini, E. Anticancer Properties of Chrysin on Colon Cancer Cells, In vitro and In vivo with Modulation of Caspase-3,-9, Bax and Sall4. *Iran. J. Biotechnol.* **2016**, *14*, 177–184. [CrossRef]

259. Kahroba, H.; Shirmohamadi, M.; Hejazi, M.S.; Samadi, N. The Role of Nrf2 signaling in cancer stemness and self-renewal to tumorigenesis and chemoresistance. *Life Sci.* **2019**, *239*, 116986. [CrossRef]

260. Liu, M.-L.; Zhang, F.; Zhang, S.-J. RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC). *Biomed. Pharmacother.* **2019**, *118*, 109250. [CrossRef] [PubMed]

261. Kirtonia, A.; Gala, K.; Fernandes, S.G.; Pandya, G.; Pandey, A.K.; Sethi, G.; Khattra, E.; Garg, M. Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. *Semin. Cancer Biol.* **2020**, *10*, 1–17. [CrossRef] [PubMed]

262. Paciello, F.; Fetoni, A.R.; Mezzogori, D.; Rolesi, R.; Di Pino, A.; Paludetti, G.; Grassi, C.; Troiani, D. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. *Sci. Rep.* **2020**, *10*, 1–17. [CrossRef] [PubMed]

263. San, T.T.; Khaenam, P.; Prachayasittikul, V.; Sripa, B.; Kunkeaw, N.; Chan-On, W. Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells. *Heliyon* **2020**, *6*, e03255. [CrossRef] [PubMed]

264. Soni, V.K.; Shukla, D.; Kumar, A.; Vishvakarma, N.K. Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1. *Int. J. Biochem. Cell Biol.* **2020**, *123*, 105752. [CrossRef] [PubMed]

265. Lu, X.; Yang, F.; Chen, D.; Zhao, Q.; Chen, D.; Ping, H.; Xing, N. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. *Int. J. Biol. Sci.* **2020**, *16*, 1121–1134. [CrossRef]

266. Xu, X.; Jiang, X.; Chen, L.; Zhao, Y.; Huang, Z.; Zhou, H.; Shi, M. MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells. *Cancer Biother. Radiopharm.* **2019**, *34*, 559–565. [CrossRef]

267. Zou, A.; Wu, A.; Luo, M.; Zhou, C.; Lu, Y.; Yu, X. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway. *Life Sci.* **2019**, *235*, 116798. [CrossRef]

268. Liu, Y.; Gu, S.; Li, H.; Wang, J.; Wei, C.; Liu, Q. SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression. *Biochem. Biophys. Res. Commun.* **2019**, *518*, 127–133. [CrossRef]

269. Tan, L.-M.; Li, X.; Qiu, C.-F.; Zhu, T.; Hu, C.-P.; Yin, J.-Y.; Zhang, W.; Zhou, H.-H.; Liu, Z.-Q. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. *J. Cancer* **2019**, *10*, 6374–6383. [CrossRef]

270. Martins, I.L.; Charniern, C.; Gandin, V.; Silva, J.L.A.F.; Justino, G.C.; Telo, J.P.; Vieira, A.J.S.C.; Marzano, C.; Antunes, A.M.M. Selenium-Containing Chrysin and Quercetin Derivatives: Attractive Scaffolds for Cancer Therapy. *J. Med. Chem.* **2015**, *58*, 4250–4265. [CrossRef]

271. Kodumudi, K.N.; Woan, K.; Gilvary, D.L.; Sahakian, E.; Wei, S.; Djeu, J. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. *Clin. Cancer Res.* **2010**, *16*, 4583–4594. [CrossRef]

272. Sekino, Y.; Han, X.; Kawaguchi, T.; Babasaki, T.; Goto, K.; Inoue, S.; Hayashi, T.; Teishima, J.; Shiota, M.; Yasui, W.; et al. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer. *Int. J. Mol. Sci.* **2019**, *20*, 3936. [CrossRef] [PubMed]
273. Tanaudommongkon, I.; Tanaudommongkon, A.; Prathipati, P.; Nguyen, J.T.; Keller, E.T.; Dong, X. Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. *Biomedicines* 2020, 8, 253. [CrossRef] [PubMed]

274. Lim, H.-K.; Kim, K.M.; Jeong, S.-Y.; Choi, E.K.; Jung, J. Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema. *Integr. Cancer Ther.* 2016, 16, 496–504. [CrossRef] [PubMed]

275. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. *Oncogene* 2003, 22, 7265–7279. [CrossRef] [PubMed]

276. Aylon, Y.; Oren, M. Living with p53, Dying of p53. *Cell* 2007, 130, 597–600. [CrossRef]

277. Nag, S.A.; Qin, J.-J.; Srivenugopal, K.S.; Wang, M.; Zhang, R. The MDM2-p53 pathway revisited. *J. Biomater. Sci. Polym. Ed.* 2013, 27, 254–271. [CrossRef]

278. Moll, U.M.; Wolff, S.; Speidel, D.; Deppert, W. Transcription-independent pro-apoptotic functions of p53. *Curr. Opin. Cell Biol.* 2005, 17, 631–636. [CrossRef]

279. Li, X.; Huang, J.-M.; Wang, J.-N.; Xiong, X.-K.; Zhang, Q.; Luo, Z.; Li, S.; Sun, Y. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway. *J. Food Biochem.* 2020, e13425. [CrossRef]

280. Bhattacharjee, S.; Li, J.; Dashwood, R. Emerging crosstalk between long non-coding RNAs and Nrf2 signaling. *Integr. Cancer Ther.* 2016, 15, 6844–6892. [CrossRef] [PubMed]

281. Li, L.; Chen, Y.; Jiao, D.; Yang, S.; Li, P. Protective Effect of Astaxanthin on Ochratoxin A-Induced Kidney Injury to Mice by Regulating Oxidative Stress-Related Nrf2/KEAP1 Pathway. *Molecules* 2020, 25, 1386. [CrossRef]

282. Wang, X.; Chang, X.; Zhan, H.; Zhang, Q.; Li, C.; Gao, Q.; Yang, M.; Luo, Z.; Li, S.; Sun, Y. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway. *J. Food Biochem.* 2020, e13425. [CrossRef]

283. Ji, L.; Zhang, R.; Chen, J.; Xue, Q.; Moghal, N.; Tsao, M.-S. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. *Sci. Rep.* 2019, 9, 12437. [CrossRef] [PubMed]

284. Wu, J.; Zhang, L.; Li, H.; Wu, S.; Liu, Z. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression. *Biochem. Biophys. Res. Commun.* 2019, 518, 698–705. [CrossRef]

285. Xia, X.; Wang, Q.; Ye, T.; Liu, Y.; Liu, D.; Song, S.; Zheng, C. Nrf2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells. *Fundam. Clin. Pharmacol.* 2020, 34, 41–50. [CrossRef] [PubMed]

286. Cucci, M.A.; Grattarola, M.; Dianzani, C.; Damia, G.; Ricci, F.; Roetto, A.; Trotta, F.; Barrera, G.; Pizzimenti, S. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism. *Free Radic. Biol. Med.* 2020, 150, 125–135. [CrossRef]

287. Gao, A.M.; Ke, Z.P.; Shi, F.; Sun, G.C.; Chen, H. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. *Chem. Biol. Interact.* 2013, 206, 100–108. [CrossRef]

288. Laredj-Bourezf, B.; Bolzinger-Thevenin, M.A.; Pelletier, J.; Chevalier, Y. Pickering emulsions stabilized by biodegradable block copolymer micelles for controlled topical drug delivery. *Int. J. Pharm.* 2017, 531, 134–142. [CrossRef]

289. Mandal, A.; Bisht, R.; Rupenthal, I.D.; Mitra, A.K. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. *J. Control. Release* 2017, 248, 96–116. [CrossRef]

290. Cabral, H.; Miyata, K.; Osada, K.; Kataoka, K. Block Copolymer Micelles in Nanomedicine Applications. *Chem. Rev.* 2018, 118, 6844–6892. [CrossRef]

291. Arranja, A.G.; Pathak, V.; Lammers, T.; Shi, Y. Tumor-targeted nanomedicines for cancer theranostics. *Pharmacol. Res.* 2017, 115, 87–95. [CrossRef]

292. Ghamkhari, A.; Pouyafar, A.; Salehi, R.; Rabharghazi, R. Chrysin and Docetaxel Loaded Biodegradable Micelle for Combination Chemotherapy of Cancer Stem Cell. *Pharm. Res.* 2019, 36, 165. [CrossRef] [PubMed]

293. Davaran, S.; Fazeli, H.; Ghamkhari, A.; Rahimi, F.; Molavi, O.; Anzabi, M.; Salehi, R. Synthesis and characterization of novel P(HEMA-LA-MADQUAT) micelles for co-delivery of methotrexate and Chrysin in combination cancer chemotherapy. *J. Biomater. Sci. Polym. Ed.* 2018, 29, 1265–1286. [CrossRef] [PubMed]
313. Mohammadi, Z.; Zak, M.S.; Seidi, K.; Barati, M.; Akbarzadeh, A.; Zarghami, N. The Effect of Chrysin Loaded PLGA-PEG on Metalloproteinase Gene Expression in Mouse 4T1 Tumor Model. *Drug Res.* 2017, 67, 211–216. [CrossRef] [PubMed]

314. Khaledi, S.; Jafari, S.; Hamidi, S.; Molavi, O.; Davaran, S. Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin. *J. Biomater. Sci. Polym. Ed.* 2020, 31, 1107–1126. [CrossRef] [PubMed]

315. Ferrado, J.B.; Perez, A.A.; Ruiz, M.C.; León, I.E.; Santiago, L.G.; Rubin, A.A.P. Chrysin-loaded bovine serum albumin particles as bioactive nanosupplements. *Food Funct.* 2020, 11, 6007–6019. [CrossRef]

316. Lotfi-Attari, J.; Soltanahmadid, Y.P.; Dadashpour, M.; Alipour, S.; Farajzadeh, R.; Javidfar, S.; Zarghami, N. Co-Delivery of Curcumin and Chrysin by Polymeric Nanoparticles Inhibit Synergistically Growth and hTERT Gene Expression in Human Colorectal Cancer Cells. *Nutr. Cancer* 2017, 69, 1290–1299. [CrossRef]

317. Mohammadinejad, S.; Akbarzadeh, A.; Rahmati-Yamchi, M.; Hatam, S.; Kachalaki, S.; Zohreh, S.; Zarghami, N. Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line. *Asian Pac. J. Cancer Prev.* 2015, 16, 3753–3758. [CrossRef]

318. Anari, E.; Akbarzadeh, A.; Zarghami, N. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. *Artif. Cells Nanomed. Biotechnol.* 2015, 44, 1410–1416. [CrossRef]

319. Javan, N.; Ansari, M.H.K.; Dadashpour, M.; Khojastehfard, M.; Bastami, M.; Rahmati-Yamchi, M.; Zarghami, N. Synergistic Anti-proliferative Effects of Co-nanoencapsulated Curcumin and Chrysin on MDA-MB-231 Breast Cancer Cells Through Uproregulating miR-132 and miR-502c. *Nutr. Cancer* 2019, 71, 1201–1213. [CrossRef]

320. Kim, K.M.; Lim, H.K.; Shim, S.H.; Jung, J. Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles. *Int. J. Nanomed.* 2017, 12, 1917–1925. [CrossRef]

321. Baidya, D.; Kushwaha, J.; Mahadik, K.; Patil, S. Chrysin-loaded folate conjugated PF127-F68 mixed micelles with enhanced oral bioavailability and anticancer activity against human breast cancer cells. *Drug Dev. Ind. Pharm.* 2019, 45, 852–860. [CrossRef]

322. Mohammadian, F.; Soltanahmadid, Y.P.; Mofarah, M.; Dastani-Habashi, M.; Zarghami, N. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. *Artif. Cells Nanomed. Biotechnol.* 2016, 44, 1972–1978. [CrossRef] [PubMed]

323. Yadav, S.; Singh, J.D. Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic RuII(η6-p-cymene) complexes. *J. Biomol. Struct. Dyn.* 2018, 37, 3337–3353. [CrossRef] [PubMed]

324. Wang, H.-J.; Zhou, Y.-Y.; Liu, X.-L.; Zhang, W.-H.; Chen, S.; Zhou, Y.; Liu, X.-W. Regioselective synthesis and evaluation of 2-amino 3-cyano chromene-chrysin hybrids as potential anticancer agents. *Bioorg. Med. Chem. Lett.* 2020, 30, 127087. [CrossRef] [PubMed]

325. Zhang, W.-H.; Chen, S.; Liu, X.-L.; Lin, B.; Zhou, Y. Study on antitumor activities of the chrysin-chromene-spirooxindole on Lewis lung carcinoma C57BL/6 mice in vivo. *Bioorg. Med. Chem. Lett.* 2020, 30, 127410. [CrossRef] [PubMed]

326. Al-Oudat, B.A.; Ramapuram, H.; Malla, S.; Audat, S.A.; Hussein, N.; Len, J.M.; Kumari, S.; Bedi, M.F.; Ashby, J.C.R.; Tiwari, A.K. Novel Chrysin-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation. *Molecules* 2020, 25, 3063. [CrossRef]

327. Mayer, S.; Keglevich, P.; Ábrányi-Balogh, P.; Szigetvári, Á.; Dékány, M.; Szántay, J.C.; Hazai, L. Synthesis and In Vitro Anticancer Evaluation of Novel Chrysin and 7-Amino-chrysin Derivatives. *Molecules* 2020, 25, 888. [CrossRef]

328. Xuan, H.; Zhang, J.-H.; Wang, Y.-H.; Fu, C.-L.; Zhang, W. Anti-tumor activity evaluation of novel chrysin–organotin compound in MCF-7 cells. *Bioorg. Med. Chem. Lett.* 2016, 26, 570–574. [CrossRef]

329. Halevas, E.; Mavroidi, B.; Antonoglou, O.; Hatzidimitriou, A.; Sagnou, M.; Pantazaki, A.A.; Litsardakis, G.; Pelecanou, M. Structurally characterized gallium–chrysin complexes with anticancer potential. *J. Biomol. Struct. Dyn.* 2020, 49, 2734–2746. [CrossRef]

330. Zhang, H.M.; Li, H.; Wang, G.X.; Wang, J.; Xiang, Y.; Huang, Y.; Shen, C.; Dai, Z.T.; Li, J.P.; Zhang, T.C.; et al. MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells. *Neoplasia* 2020, 22, 220–230. [CrossRef]

331. Zhang, L.; Liu, X.; Song, L.; Zhai, H.; Chang, C. MAP7 promotes migration and invasion and progression of human cervical cancer through modulating the autophagy. *Cancer Cell Int.* 2020, 20, 17–18. [CrossRef]
332. Liang, G.; Ling, Y.; Mehrpour, M.; Saw, P.E.; Liu, Z.; Tan, W.; Tian, Z.; Zhong, W.; Lin, W.; Luo, Q.; et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. *Mol. Cancer* 2020, 19, 65. [CrossRef] [PubMed]

333. Pan, Z.; Wu, C.; Li, Y.; Li, H.; An, Y.; Wang, G.; Dai, J.; Wang, Q. LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. *Biomed. Pharmacother.* 2019, 122, 109707. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).